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ABSTRACT
Despite advances in medical therapy and interventional procedures, heart failure
carries a dismal prognosis. Calcium has a central role in controlling the contractility
of the heart, and the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) is a key player
in calcium cycling in the cardiomyocyte. The expression and activity of SERCA2a
have been shown to be decreased in cardiac dysfunction, resulting in inefficient
relaxation of the cardiomyocytes. Another player in cardiac modulation is
neuropeptide Y (NPY), a sympathetic nervous system neurotransmitter. NPY takes
part in many processes in the heart, e.g. excitation–contraction coupling and calcium
signaling.
These two factors were assessed in a model of doxorubicin-induced heart failure
as well as in models of obesity and type 2 diabetes. Doxorubicin (DOX) is an
effective anticancer drug but its use is limited by dose-dependent cardiomyopathy
for which there is no clinically validated treatment. The therapeutic potential of
lentiviral-mediated SERCA2a gene therapy was studied in this DOX-induced model
of heart failure. Next, transgenic mice overexpressing NPY (OE-NPYDβH) were 
studied in the same model. Lastly, the OE-NPYDβH mice were examined in a model
of diet-induced obesity and type 2 diabetes, both associating strongly with
pathological changes in the heart.
DOX treatment evoked significant cardiotoxicity, resulting in a disturbance in
the expression levels of the genes involved in calcium cycling, and a slight decline
in myocardial function. Furthermore, lentiviral SERCA2a gene transfer was able to
improve the function of the heart. In OE-NPYDβH mice, DOX impaired lean mass
accumulation; moreover, the observed tendency to a greater decline in myocardial 
function may imply that NPY overexpression increases the susceptibility to DOX-
induced cardiotoxicity. Additionally, overexpression of NPY led to a cardiovascular
phenotype resembling diet-induced obesity in some respects.
In summary, these results provide further knowledge about the role of SERCA2a
and NPY in the pathological processes of heart failure, and may help to clarify the 
therapeutic potential of enhancing calcium cycling.
KEYWORDS: heart failure, calcium signaling, SERCA2a, neuropeptide Y,
doxorubicin, gene therapy, obesity, type 2 diabetes
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TIIVISTELMÄ
Lääkkeellisten ja kirurgisten hoitojen kehityksestä huolimatta sydämen vajaa-
toiminnan ennuste on huono. Sydämen supistuvuuden säätelyssä kalsiumilla on
tärkeä rooli. Kalsiumin kierron keskeinen tekijä sydänlihassolussa on sarko-
plasmisen kalvoston Ca2+ ATPaasi (SERCA2a). Sydämen vajaatoiminnassa
SERCA2a:n määrän on todettu vähenevän ja aktiivisuuden laskevan, mikä johtaa
sydänlihassolun puutteelliseen relaksaatioon. Sydämen toiminnan säätelyyn 
osallistuu myös sympaattisen hermoston välittäjäaine, neuropeptidi Y (NPY), jonka
vaikutukset välittyvät sydämen soluihin hermoston lisäksi osin myös suorien 
reseptorivaikutusten kautta. NPY vaikuttaa muun muassa sydänlihassolun kalsium-
virtoihin ja supistuvuuteen.
Näitä kahta sydämen säätelyn osatekijää tutkittiin doksorubisiinin indusoimassa
sydämen vajaatoimintamallissa ja lihavuuden sekä tyypin 2 diabeteksen malleissa.
Doksorubisiini on tehokas syövän hoidossa käytetty lääke, mutta käyttöä rajaa sen
aiheuttama sydänlihassairaus, johon ei tunneta kliinisesti validoitua hoitoa.
Doksorubisiinimallin yhteydessä arvioitiin myös lentivirusvälitteisen SERCA2a-
geeniterapian potentiaalia. NPY:tä siirtogeenisesti yli-ilmentäviä hiiriä
(OE-NPYDβH) tutkittiin doksorubisiinimallissa ja lisäksi kokeellisissa lihavuuden
sekä tyypin 2 diabeteksen malleissa, joissa on todettu esiintyvän sydämen
patologisia muutoksia.
Doksorubisiini johti sydämen kalsiumin kiertoon vaikuttavien geenien
ilmenemisen häiriöön ja sydämen toiminnan lievään alenemiseen. SERCA2a-
geeniterapia paransi sydämen toimintaa. OE-NPYDβH-hiirillä doksorubisiini esti
rasvattoman massan kasvua ja havaittu tendenssi voimakkaampaan sydämen
toiminnan heikentymiseen saattaa viitata siihen, että NPY:n yli-ilmentäminen
altistaa doksorubisiinin indusoimalle sydäntoksisuudelle. Lisäksi NPY:n yli-
ilmentämisen todettiin johtavan runsasrasvaisen ruokavalion aiheuttaman
lihavuuden ilmiasua muistuttavaan kardiovaskulariseen ilmiasuun.
Väitöskirjan tulokset tarjoavat uutta tietoa SERCA2a:n ja NPY:n roolista
sydämen vajaatoiminnan patologisissa prosesseissa ja auttavat kalsiumsignaloinnin 
tehostamisen terapeuttisen potentiaalin selvittämisessä. 
AVAINSANAT: sydämen vajaatoiminta, kalsiumsignalointi, SERCA2a,
neuropeptidi Y, doksorubisiini, geeniterapia, lihavuus, tyypin 2 diabetes 
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ACh  Acetylcholine 
AAV Adeno-associated virus
ATPase Adenosine triphosphatase
AHA American Heart Association
ANP Atrial natriuretic peptide
Beta1R Beta-1 adrenergic receptor
BMI Body mass index
BW Body weight
BNP Brain natriuretic peptide
Ca2+ Calcium ion
COL I Collagen I
COL1a2 Collagen I alpha 2
COL III Collagen III
DNA Deoxyribonucleic acid
DIO Diet-induced obesity
DβH Dopamine-beta-hydroxylase
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EF Ejection fraction
ELLA Eläinkoelautakunta; National Animal Experimental Board
EDV End-diastolic volume
ESV End-systolic volume
EASD the European Association for the Study of Diabetes
EMA the European Medicines Agency
ESC the European Society of Cardiology 
FGF Fibroblast growth factor
FDA the Food and Drug Administration
FS Fractional shortening
GTT Glucose tolerance test
GFP Green fluorescent protein
HF Heart failure
HFpEF Heart failure with preserved ejection fraction
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HFrEF Heart failure with reduced ejection fraction
HR Heart rate
HW Heart weight
HFD High fat diet
HEK293T Human embryonic kidney 293T cells
ITT Insulin tolerance test
IL-1β Interleukin 1 beta
IL-6 Interleukin 6 
IL-10 Interleukin 10
IRES Internal ribosome entry site
ICLAS the International Council of Laboratory Animal Science
i.p. Intraperitoneal
i.v. Intravenous
IVSs Intraventricular septum in systole
LVEDD Left ventricular end-diastolic diameter
LVESD Left ventricular end-systolic diameter
LVIDd Left ventricular internal diameter in diastole
LVIDs Left ventricular internal diameter in systole
LVmass Left ventricular mass
LVPWs Left ventricular posterior wall in systole
LVpres Left ventricular pressure
MMP2 Matrix metalloproteinase 2
MMP9 Matrix metalloproteinase 9
MMP13 Matrix metalloproteinase 13
MAP Mean arterial pressure
mRNA Messenger ribonucleic acid
OE-NPYDβH Mouse model overexpressing NPY under DβH promoter
MOI Multiplicity of infection
α-MHC Myosin heavy chain alpha
β-MHC Myosin heavy chain beta
NPY Neuropeptide Y
Npy1R Neuropeptide Y Y1-receptor
Npy2R Neuropeptide Y Y2-receptor
Npy5R Neuropeptide Y Y5-receptor
NO Nitric oxide
L-NNA N-nitro-L-arginine; Nitric oxide synthase inhibitor
n.s. Not significant
PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 1 alpha
PGC-1β Peroxisome proliferator-activated receptor gamma coactivator 1 beta
PE Phenylephrine
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PCR Polymerase chain reaction
PET Positron emission tomography
qNMR Quantitative nuclear magnetic resonance
qPCR Quantitative polymerase chain reaction
ROS Reactive oxygen species
RNA Ribonucleic acid
RyR2 Ryanodine receptor 2
SERCA2a Sarcoplasmic reticulum Ca2+ ATPase
α-SMA Smooth muscle actin alpha
SNP Sodium nitroprusside
SEM Standard error of the mean
STZ Streptozotocin
SNS Sympathetic nervous system
TL Tibia length
TU/ml Transducing units/ml
TGF-β1 Transforming growth factor beta 1
TNF-α Tumor necrosis factor alpha
T2D Type 2 diabetes
TH Tyrosine hydroxylase
VEGF Vascular endothelial growth factor
WD Western type diet
WT Wild-type
wo Week old
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1 Introduction
Heart failure (HF) is, beyond question, a major health issue, in fact it is the leading
global cause of morbidity and mortality (Oh, et al. 2019). The prevalence of HF is
still increasing due to the ageing of the population, and it has been estimated that the
total costs of HF will more than double by 2030 from the year 2012 (Heidenreich,
et al. 2013). HF is a broad term for a large number of pathophysiological elements
manifesting as a common syndrome; the failure to pump enough blood to meet the
demand of the organs. Manifestations may appear at many levels; for example, 
structural abnormalities in myocardium or in the coronary arteries; functional
abnormalities in valves or arrhythmias; triggered by circulating substances such as
sympathetic nervous system transmitters, natriuretic peptides and cytokines as well
as being driven by other factors such as toxic drugs, obesity and diabetes (Jessup &
Brozena 2003). Hypertension, myocardial infarction and valvular heart disease are
common causes of HF, each of them having their own pathophysiological
mechanism. On the other hand, inflammation and toxic mechanisms impair the heart
in rather different ways. Pathophysiological factors promote a process of left
ventricular remodeling resulting in hypertrophy, interstitial fibrosis and/or dilatation,
leading eventually to permanent deleterious effects on the heart (Jessup & Brozena
2003). 
Despite advances in medical therapy and invasive procedures, the prognosis of
advanced HF remains dismal. To discover more efficient treatment methods, there
is a strong need to understand more profoundly the diverse pathophysiological
mechanisms behind the processes leading to the different types of HF. In this thesis, 
the attention has been focused on two significant mechanisms in the regulation of
the heart, calcium signaling and the sympathetic neurotransmitter, neuropeptide Y
(NPY). In the cardiomyocyte, the action potential initiates the cascade of excitation– 
contraction coupling, and calcium cycling plays a key role in this process. It is
essential for proper relaxation phase that the calcium released in the contraction 
phase is efficiently extruded from the cytosol. It is recognized that disturbances in
calcium cycling are common in the damaged heart (Olson 2004). NPY takes part in
a vast number of processes in the heart, such as excitation–contraction coupling and 
the modulation of calcium currents in cardiomyocytes. The main function of NPY is 
13 
 
    
  
  
      
       
  
  
    
  
 
     
  
    
    
       
   
     
      
 
neuronal modulation, but in addition, NPY exerts direct effects on the cardiac cells.
Besides, NPY has been connected with several types of cardiovascular pathologies
(McDermott & Bell 2007). 
The studies in this thesis investigated both calcium signaling and NPY, as well
as the potential of exploiting calcium cycling enhancing gene therapy in the
framework of particular types of cardiac pathologies. First, doxorubicin (DOX) is 
one of the most efficient cytotoxic drugs used in clinical practice to treat various
types of cancers. The main adverse effect of DOX is cardiotoxicity, leading to
cardiomyopathy and HF. Furthermore, major epidemic-scale health challenges,
obesity and type 2 diabetes, associate strongly with pathological changes in the heart, 
and eventually lead to HF, though the exact nature of these associations is not
completely clear. 
This work employs animal models and viral mediated gene therapy, which are
useful tools in unravelling the underlying disease mechanisms and for assessing new 
treatment methods, since the initiation of clinical trials requires convincing evidence 
of efficacy and safety from preclinical research. With increasing knowledge, we are 
able to gain a deeper understanding about the molecular mechanisms behind HF and 
to help to clarify the possibilities of calcium cycling -targeted gene therapy.
14
 
     
  
          
      
   
  
    
    
        
  
      
     
  
        
       
  
  
    
          
      
    
     
       
       
        
   
   
    
       
     
  
2 Review of the Literature
2.1 Heart failure
The classic definition of HF describes it as the inability of the heart to provide
sufficient perfusion to organs for filling the requirements of the body (Reddy &
Borlaug 2016). Rather than a uniform disease, this inability emerges in the spectrum
of symptoms, which create a common syndrome. HF is diagnosed by its symptoms, 
a physical examination and diagnostic testing of the patients, and the underlying 
causes consist of several pathophysiological factors and comorbidities complicating
both diagnosis and treatment (Metra & Teerlink 2017, Snipelisky, et al. 2019). HF
may emanate for example from defects in the myocardium, coronary arteries, 
pericardium, heart valves, conduction system, or from a combination of these defects
(Mazurek & Jessup 2017, Snipelisky, et al. 2019). The HF syndrome is advancing;
the activated neurohormonal regulation and an upregulated sympathetic nervous
system (SNS) initially assist the heart to maintain cardiac output by boosting heart
rate (HR) and stroke volume, but in the long term, these alterations permanently 
damage the heart (Mazurek & Jessup 2017). 
Heart dysfunction has traditionally been categorized as systolic or diastolic HF, 
however, according to present knowledge, HF is classified as heart failure with
reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction
(HFpEF) (Reddy & Borlaug 2016). In HFrEF, a cardiac injury leads to the
development of myocardial dysfunction, and via a worsening of symptoms, to the
end-stage heart failure (Oh, et al. 2019). The concept of HFpEF still raises some
differing opinions and it may have been previously considered less harmful than
HFrEF. However, HFpEF may account for nearly half of all HF diagnoses (Carbone, 
et al. 2019). In HFpEF, a systemic proinflammatory state and the production of
reactive oxygen species have been hypothesized to result in hypertrophy of
myocytes, increased fibrosis, and decreased left ventricular capabilities (Oh, et al.
2019). Treatment of HFpEF has been challenging, and there are no evidence-based
therapies which are shown to improve outcomes in HFpEF, probably due to the vast
heterogeneity of the HFpEF syndrome (Reddy & Borlaug 2016, Metra & Teerlink
2017, Oh, et al. 2019). 
15 
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The view about how HF should be treated has shifted over the course of time.
Looking back from year 1989, the first treatments were based on increasing inotropy 
and decreasing preload. Next, reducing afterload was demonstrated to relieve
symptoms and prolong life. This was followed by an understanding of the
importance of relaxation and treating HF by increasing lusitropy. Thereafter, the next
strategy was to preserve the failing heart by reducing preload, afterload and inotropy 
(Katz 1989). During the past three decades, as knowledge about the pathophysiology
of HF has accumulated, the treatment of HF, utilizing medical therapy, coronary
revascularization and device therapy, has advanced significantly (Reddy & Borlaug 
2016, Mazurek & Jessup 2017). Nonetheless, HF is still one of the main causes of
hospitalization in the elderly population (Mazurek & Jessup 2017).
2.2 Calcium cycling in the heart
The contraction–relaxation cycle of the heart is controlled by a delicate balance in
the intracellular regulation of calcium concentration in cardiomyocytes. 
In excitation–contraction coupling, as a result of membrane depolarization, a small
amount of calcium entering the cell through L-type Ca2+ channels triggers the
co-operation with the ryanodine receptor 2 (RyR2) stimulating the release of a higher
calcium amount from the sarcoplasmic reticulum (Fig. 1) (Hajjar, et al. 2000). In this
process, the intracellular calcium concentration rises tenfold, from 0.1 µm to 1 µm
(Gianni, et al. 2005). The elevated cytosolic calcium concentration facilitates the 
interaction between actin and myosin in myofibrils, resulting in contraction
(MacLennan & Kranias 2003). In the relaxation phase, calcium is extruded from the
cytosol to the extracellular space by Na/Ca2+ exchanger and Ca2+ ATPase, and
reaccumulated in the sarcoplasmic reticulum by sarcoplasmic reticulum Ca2+ 
ATPase (SERCA2a) (Fig. 1). In mammals, sarcoplasmic calcium uptake is the
dominant cytosolic calcium removal process (Bers 1997). Phospholamban (PLN),
in its non-phosphorylated form, inhibits SERCA2a (James, et al. 1989).
16
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Review of the Literature
Figure 1. Calcium cycling in a cadiomyocyte. Calcium enters the cell through L-type Ca2+ channels
and the ryanodine receptor 2 subsequently releases a greater amount of calcium from
the sarcoplasmic reticulum, leading to contraction. During relaxation, calcium is 
reaccumulated into sarcoplasmic reticulum by SERCA2a and extruded from the cell by
Na/Ca2+ exchanger and Ca2+ ATPase. Modified from Hajjar, et al. 2000, MacLennan
2003.
2.2.1 Sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a)
2.2.1.1 General introduction
The mammalian genome harbors three different genes for SERCA; SERCA1, which
is present in fast-twitching skeletal muscle, SERCA2, and SERCA3, which can be
detected in several nonmuscle cell types (Gianni, et al. 2005). SERCA2 encodes a 
transcript for two separate isoforms, SERCA2a being expressed mainly in the
cardiac muscle and SERCA2b in the smooth muscle (Martonosi & Pikula 2003).
The data available on the distribution of SERCA2a in the heart is scarce, and
furthermore, the structure of SERCA2a remained a mystery until very recently when 
the first crystal structures, originating from pig heart, were published (Eisner, et al.
2017, Sitsel, et al. 2019). SERCA2a, a 125 kDa protein, consists of three cytoplasmic
domains regulating ATP binding, autophosphorylation and dephosphorylation, and
a transmembrane domain controlling Ca2+ binding and translocation. Several
proteins regulate SERCA2a, including PLN, S100A and Sumo1, however, PLN is
the main regulatory protein and the only one known to be directly involved in the
development of cardiac disease (Federico, et al. 2019, Zhihao, et al. 2019). 
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2.2.1.2 The role of SERCA2a in calcium signaling and therapeutics
SERCA2a has a key role in extruding calcium from cytosol, albeit the proportion of
extruded calcium varies between the Na/Ca2+ exchanger and SERCA2a in a species-
dependent manner (Bers 1997). In rodents, SERCA2a extrudes approximately
90–92% of cytosolic calcium while in humans, the corresponding proportion is 76%
(Milani-Nejad & Janssen 2014). Moreover, the process of excitation–contraction 
coupling relies not only on the properties and amplitude of calcium channels and
transporters, but also on their appropriate synchronization and spatial arrangement
(Eisner, et al. 2017, Gambardella, et al. 2018). 
As first reported in 1987, abnormal calcium handling was found in patients with
end-stage HF (Gwathmey, et al. 1987). This provided the first direct evidence about
the role of calcium in the function of the heart. Since then, the central role of
SERCA2a in the process of maintaining intracellular calcium homeostasis in the
heart has been clearly demonstrated. Moreover, diminished SERCA2a expression
and activity in both human and experimental animal models of HF have been 
demonstrated (Schmidt, et al. 1998, Hajjar, et al. 2000, Olson 2004). In a recent
review, post-translational modifications in SERCA2a and in the other main
modulators of calcium cycling, PLN and RyR2, were highlighted to play an 
important role in regulating calcium homeostasis (Federico, et al. 2019). At present, 
abnormal sarcoplasmic calcium handling in failing cardiomyocytes is seen as the
primary defect that causes contractile dysfunction (Zima, et al. 2014).
At the turn of the millennium, enhancing sarcoplasmic calcium transport was
seen as a potential therapeutic modality (Hajjar, et al. 2000). SERCA2a gene transfer
was studied in several experimental animal HF models utilizing viral gene delivery
vectors and the results were rather promising with regard to restoring SERCA2a
expression and improving systolic and diastolic function in failing hearts
(Miyamoto, et al. 2000, Sakata, et al. 2007, Kawase, et al. 2008, Niwano, et al. 2008,
Prunier, et al. 2008). In the field of clinical research, a phase 2 SERCA2a-mediated
CUPID trial (Calcium Upregulation by Percutaneous Administration of Gene
Therapy in Cardiac Disease) in patients with advanced HF reported very favorable
results (Jessup, et al. 2011, Zsebo, et al. 2014), but unfortunately the subsequent
phase 2b trial was a major disappointment (Greenberg, et al. 2014, Greenberg, et al.
2016). Another phase 2 trial, AGENT-HF, was terminated prematurely because of
the CUPID trial results, and again, no improvements had been evident in the small 
number of patients treated (Hulot, et al. 2017). These failures could well be attributed
to either inefficient delivery route or too low dose of the viral vector, and not because 
of the SERCA2a product itself. The CUPID trial and several other gene therapy trials
utilized antegrade coronary artery infusion to deliver the viral vectors (Jessup, et al.
2011, Shareef, et al. 2014, Hayward, et al. 2015). Further analysis revealed that the
transduction rate of the SERCA2a gene was much lower in the CUPID phase 2b trial
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than in the previous phase 2 trial. Inadequate delivery by intracoronary route and
lower transduction efficiency possibly due to a change in the proportion of empty 
viral capsid as compared to phase 1 have been discussed as being the main factors
behind the negative results (Mingozzi, et al. 2013, Greenberg, et al. 2016, Gabisonia
& Recchia 2018, Ishikawa, et al. 2018). However, in these clinical trials, the
SERCA2a gene transfer was confirmed to be safe and feasible. 
2.3 Neuropeptide Y (NPY)
2.3.1 General introduction
NPY is a 36 amino acid neurotransmitter, first isolated in the early 1980s (Tatemoto
1982). NPY is expressed in the central nervous system, being one of the most
abundant peptides in the brain (Hirsch & Zukowska 2012). In the peripheral SNS, 
NPY is co-localized and co-released with catecholamines (i.e. adrenaline and
noradrenaline). NPY has a 92% sequence homology in cartilaginous fish and
mammals, suggesting that it serves important roles in physiology (Hirsch &
Zukowska 2012). NPY certainly participates in a vast number of biological processes
e.g. cortical neural excitability, stress response, food intake, circadian rhythms, and
cardiovascular function (Yi, et al. 2018). In the central nervous system, NPY is
known to mediate an orexigenic effect. When administered as a long-term central
infusion, NPY leads to obesity by increasing food intake, fostering lipogenesis in the
liver and white adipose tissue, as well as increasing plasma insulin, corticosterone
and triglyceride levels (Zarjevski, et al. 1993). In the SNS, NPY is released primarily
in conditions of prolonged activation of the sympathetic nerves as in stress
conditions (Kuo, et al. 2007). In the central nervous system, NPY inhibits excessive
activation of the stress response, whereas, in the periphery, NPY has been shown to 
amplify the stress response (Hirsch & Zukowska 2012). NPY is widely expressed in
the periphery in a vast number of tissues including the nerve fibers innervating blood
vessels (Ekblad, et al. 1984) and the heart (Gu, et al. 1984). In the heart, NPY is the
most abundant neuropeptide (McDermott & Bell 2007).
2.3.2 NPY receptors and role in heart
The effects of NPY are mediated via the six identified G protein-coupled receptor
subtypes (Y1, Y2, “Y3”, Y4, Y5, and y6). Five of the receptors have been cloned
from mammals (Y1, Y2, Y4, Y5, and y6), of which Y1, Y2, Y4 and Y5 are functional
in humans and have been cloned from human tissues in 1992–1996 (Brothers &
Wahlestedt 2010, Yi, et al. 2018). Receptors Y1, Y2 and Y5 mediate the main 
functional responses in the heart (McDermott & Bell 2007). 
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In the heart, NPY has been demonstrated to participate in an extensive number
of processes affecting neuronal control, the excitation–contraction coupling and the
contractility of ventricular cardiomyocytes as well as cellular growth and blood 
supply (Fig. 2) (McDermott & Bell 2007, Dvorakova, et al. 2014). The net effect of
NPY-activated pathways varies or even can be opposite between distinct cell types
(Tan, et al. 2018). Concerning the cardiovascular system, receptor Y1 modulates
calcium transients and increases the intracellular Ca2+ level in both cardiomyocytes
and ventricular endocardial endothelial cells leading to a positive inotropic effect 
(Heredia, et al. 2005, Jacques & Abdel Samad 2007, Jacques, et al. 2017). In 
vascular smooth muscle cells, the activation of Y1-receptor stimulates protein 
degradation and mitogenesis (Zhu, et al. 2015, Tan, et al. 2018). In addition, 
Y1-receptor activation contributes to the sympathetic stimulation that potentiates
noradrenaline-induced vasoconstriction (Tan, et al. 2018). Receptor Y2 takes part in 
the crosstalk between sympathetic and parasympathetic neurotransmission. The
Y2-receptor modulates noradrenaline and NPY secretion in the myocardium at the
presynaptic level, and mediates slowing of the HR (McDermott & Bell 2007,
Brothers & Wahlestedt 2010). In addition, activation of Y2-receptor is involved in 
promoting angiogenesis (McDermott & Bell 2007). In comparison to the other NPY 
receptors, the Y-receptor 5 contains an additional 100 amino acid sequence (Tan, et
al. 2018). The Y5-receptor contributes to protein turnover, and it has been shown to
function synergistically with the Y1-receptor to modulate vasomotion and 
mitogenesis, and to promote vascular angiogenesis and arteriogenesis with Y2-
receptor (Fig. 2) (Brothers 2010, Tan 2018). Taken together, the effects of NPY in
the heart are multifaceted and mediated via SNS or via a direct interaction with
receptors in the target cells.
Since the 1980s, the role of NPY in the pathophysiology of the heart has been
the focus of intensive study. NPY has been linked, via diverse mechanisms, in 
different types of cardiovascular diseases with some conflicting evidence 
(McDermott & Bell 2007, Dvorakova, et al. 2014, Tan, et al. 2018). There is a 
consensus that elevated plasma NPY levels do correlate with the severity of HF
(Ullman, et al. 1994, Persson, et al. 2002, Cuculi, et al. 2013, Shanks & Herring 
2013, Dvorakova, et al. 2014, Ajijola, et al. 2019). 
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Figure 2. The physiological and pathophysiological role of neuropeptide Y in the heart.
Neuropeptide Y acts in the heart via both the sympathetic nervous system and direct
receptor signaling in a multifaceted way. Modified from McDermott 2007.
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Deleterious effects of NPY in a compromised heart, marked with red colour in Fig. 
2, include detrimental maintenance of contractile performance driven by increased
sympathetic activity and inhibition of the vagally mediated parasympathetic
response, together increasing HR (Ilebekk, et al. 2005, Tan, et al. 2018). 
Furthermore, the demonstrated direct unfavorable contribution of NPY involves also 
a reduced degradation and increased synthesis of proteins leading to an increased
cardiac mass (Millar, et al. 1994, Bell, et al. 2002) and activation of cardiac
fibroblasts promoting fibrosis (Zhu, et al. 2015). However, in vascular smooth
muscle cells, the activation of receptor Y1 in pathological conditions has been
reported to result in an elevated degradation of proteins (Tan, et al. 2018). The NPY-
modulated remodeling effect in myocardial tissue may be beneficial in the short-
term, but in the long run, it can lead to hypertrophy (McDermott & Bell 2007). In
addition, NPY has been demonstrated to have an effect on cardiomyocyte
mitochondria, impairing mitochondrial function and energy metabolism (Luo, et al.
2015, Hu, et al. 2017). At the receptor level, the gene expression of Y1 has been
reported to decline in conjunction with the severity of hypertrophy while Y2
expression has been reported to increase in failing heart. These changes are believed 
to reflect a pathological role for Y1 in the development of cardiac hypertrophy and
respectively, a compensatory role for Y2 as an angiogenic factor (Callanan, et al.
2007, Jacques & Abdel Samad 2007).
2.3.3 The model of transgenic NPY overexpression
The transgenic OE-NPYDβH mouse model, generated earlier in our laboratory, 
overexpresses Npy in the peripheral SNS system and in the noradrenergic system of
the brain (Ruohonen, et al. 2008, Vähätalo, et al. 2015). In the OE-NPYDβH mouse
model, Npy expression is driven under the dopamine-β-hydroxylase promoter (DβH)
targeting the transgene expression to noradrenergic neurons with very little evidence 
for ectopic expression (Ruohonen, et al. 2008). A single nucleotide polymorphism
NPY L7P, having highest allele frequencies in northern countries, has been
recognized as a risk factor for type 2 diabetes and cardiovascular diseases (Pesonen 
2008). The targeted overexpression of Npy in the OE-NPYDβH mouse model
recapitulates situations of NPY excess in chronic mild stress and this kind of
polymorphism of NPY in humans (Ruohonen, et al. 2012, Vähätalo, et al. 2016). 
Compared to normal wild-type (WT) mice, the homozygous OE-NPYDβH mice have
been shown to express about a twofold elevated Npy level in the noradrenergic
neurons of brain and a significantly higher expression in the adrenal glands
(Vähätalo, et al. 2015). OE-NPYDβH mice have been shown to exhibit a metabolic
syndrome -like phenotype with adult-onset obesity, dyslipidemia and impaired
glucose tolerance (Ruohonen, et al. 2008, Vähätalo, et al. 2015, Vähätalo, et al.
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2016). The mechanisms leading to OE-NPYDβH phenotype are mediated mainly via 
inhibition of adrenergic tone in metabolic tissues instead of NPY causing direct
effects on adipose tissue and the liver (Vähätalo, et al. 2016). This is characterized
by decreased expression of the rate-limiting enzyme in noradrenaline synthesis,
tyrosine hydroxylase (Th) in the brain and the adrenal gland, changes in the
expression of beta adrenergic receptor in the target tissue, and reduced urinary 
adrenaline levels (Ailanen, et al. 2017). In addition, the OE-NPYDβH mice have been 
shown to be more susceptible to endothelial damage-induced vascular wall
hypertrophy, with an increased formation of the neointima (Ruohonen, et al. 2009). 
2.4 Doxorubicin (DOX)
2.4.1 General introduction
Doxorubicin (DOX) is a member of the anthracycline family of drugs. It was first
isolated in the early 1960s and incorporated into anticancer practice in the late 1960s. 
DOX is a nonselective class I agent and its principal mechanism of action is to inhibit 
topoisomerase I and II and interfere with the uncoiling of DNA, a process eventually
resulting in programmed cell death (Tacar, et al. 2013). The efficacy of DOX was 
quickly noticed and it has been used to treat several types of cancers, including solid 
tumors, leukemia and lymphomas (Octavia, et al. 2012). The adverse effects include
hematopoietic suppression, myelosuppression, nausea, vomiting, extravasation,
alopecia and cardiotoxicity (Singal & Iliskovic 1998, Octavia, et al. 2012). In fact, 
the major limitation associated with the use of DOX is toxicity affecting the
myocardium, leading to myocardial dysfunction, induction of dose-dependent
cardiomyopathy and ultimately to congestive heart failure (Umlauf & Horký 2002,
Chatterjee, et al. 2010, Renu, et al. 2018). DOX-induced toxicity may drive wall
motion abnormalities and/or dilatation with HFpEF, though this may be a precursor
state to HFrEF (Del Buono, et al. 2018). After treatment with DOX or its derivatives, 
cardiac complications will occur in about 10% of cancer patients within 10 years
after the termination of the chemotherapy (Octavia, et al. 2012). In a recent registry
study concerning various anticancer therapies, severe cardiotoxicity led to a 10-fold 
increase in total mortality when compared to patients with a milder form or without
cardiotoxicity (Lopez-Sendon, et al. 2020). Among cancer survivors, anthracycline-
induced heart disease has been shown to be a major cause of morbidity and mortality
(Ghigo, et al. 2016). There are some strategies to reduce the adverse cardiovascular
effects of DOX, such as modulating the dosage, liposomal formulation of DOX, 
administering erythropoietin due to apoptosis inhibition, or dexrazoxane due to free
iron chelation, and utilizing beta-adrenergic antagonists or angiotensin-converting 
enzyme inhibitors (Octavia, et al. 2012, Wenningmann, et al. 2019, D'Oria, et al.
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2020). Furthermore, synthetic flavonoids have been evaluated for their radical-
scavenging and chelative properties with encouraging results (van Acker, 
et al. 2001, Octavia, et al. 2012). However, no prevention or complete treatment for
the DOX-induced HF has been identified (Ghigo, et al. 2016). Nonetheless, DOX 
has still today a role in clinical practice as it is one of the most effective anticancer
drugs ever developed.
2.4.2 Mechanism of DOX-induced cardiotoxicity
The knowledge of the causal mechanisms of DOX-induced cardiotoxicity still
remains incomplete, however, in particular the cardiomyocytes might be susceptible 
to the long-term adverse effects as they do not regenerate to any significant extent
(Kalyanaraman 2019). Putative mechanisms for cardiotoxicity include the formation 
of reactive oxygen species leading to oxidative stress, apoptosis, mitochondrial
dysfunction and altered molecular signaling (Fig. 3) (Cappetta, et al. 2018). DOX-
induced cardiotoxicity has been associated with increased SNS activity (Tong, et al.
1991, Bartoli, et al. 2011) as the increased reactive oxygen species level may elevate 
sympathetic tone (Renu, et al. 2018). Furthermore, reactive oxygen species activate 
matrix metalloproteinase enzymes that are responsible for the degradation of the
extracellular matrix, which is an important platform for the cardiomyocytes to attach
(D'Oria, et al. 2020). Oxidative stress might be a significant contributor in DOX-
induced cardiotoxicity since the myocardium is a redox-sensitive target with an 
inadequate antioxidant defence mechanism (Kalyanaraman 2019, D'Oria, et al.
2020). Moreover, DOX and doxorubicinol, its metabolite formed in cardiac tissue,
bind to the SERCA2a and alter its activity detrimentally (Fig. 3) (Hanna, et al. 2014). 
Furthermore, since it is more prone to damage than nuclear DNA, the disruption of
mitochondrial DNA might play a significant role in developing HF (Chen, et al.
2019). DOX intercalates with DNA bases and mediates double-strand DNA
breakage through blocking the activity of the topoisomerase II-beta (Fig. 3) (Renu, 
et al. 2018). In addition to decreasing the expression of SERCA2a and RyR2, DOX 
induces an inappropriate opening of the ryanodine receptors (Gambliel, et al. 2002, 
Octavia, et al. 2012, Tocchetti, et al. 2014).
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Figure 3. The effects of doxorubicin on the heart. Doxorubicin induces various pathological
processes in the heart, including increased sympathetic activity, oxidative stress,
damage in DNA, disturbances in calcium cycling and in mitochondria, and increased 
apoptosis and fibrosis. Modified from Cappetta et al. 2018.
2.4.3 The model of DOX-induced heart failure
DOX-induced HF has been studied in various experimental settings. The first mouse 
studies date back to the beginning of the current century. DOX has been typically
administered by intraperitoneal injection (i.p.) either as one larger dose (usually
10–20 mg/kg) or as weekly dosing with the cumulative dose being in the same range. 
Furthermore, DOX-induced cardiotoxicity has been studied utilizing a vast number
of genetically modified mouse models, seeking to unravel different aspects of
cardiotoxicity, such as DOX metabolism, DNA damage, oxidative stress, apoptosis,
necrosis, autophagy and mitophagy, as reviewed thoroughly by Chen et al. (2019). 
Here, the focus is limited to WT mouse models of HF. The characteristic findings of 
DOX-induced cardiotoxicity include repressed cardiac function, increased fibrosis
and apoptosis, and decreased survival. In addition, numerous genes have been shown 
to be either upregulated or downregulated by DOX. The effects of DOX-induced
cardiotoxicity on WT mice heart are summarized in Table 1.
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Table 1. Doxorubicin-induced cardiotoxic effects on the heart of wild-type mice.
Dose + Strain Functional changes Other changes Reference
20 mg/kg single i.p. Day 9: EF, FS ↓ Day 9: weight, survival ↓ Olson, et al.
Male C57BL/6J/129S6 LVEDD, LVESD ↑ Day 18: necrosis ↑ 2003
20 mg/kg single i.p. Day 5: FS ↓ Day 5: apoptosis, cytokine Nozaki et al.
Male C57BL/6 LVEDD LVESD ↑ production ↑ survival ↓ 2004
20 mg/kg single i.p.
Male Balb/c Day 6: FS, LVEDD ↓
Day 7: BW, survival ↓ 
apoptosis, myofibrillar loss ↑
Li et al. 
2006
20 mg/kg single i.p.
4 mg/kg / week x 5
Male C57BL/6
Day 5: EF, FS, LVIDd ↓
Week 12/16: EF, FS ↓
LVIDd, LVIDs ↑
Day 1: apoptosis ↑
6/12/16 weeks: survival ↓
Neilan et al.
2006
20 mg/kg single i.p.
C57BL/10ScSn Day 5: EF, LVpres ↓ TNF-α, apoptosis ↑
Riad, et al.
2008
15 mg/kg single i.p. Day 2: α-Mhc,Bnp,Serca2a ↓ Ito, et al.
Male C57BL/6 Day 28: HW/BW ↑ survival ↓ 2009
18 mg/kg single i.p. Day 8: BW, HW/BW, survival ↓ Zhu, et al.
Balb/c Day 14: myofibrillar loss ↑ 2010
12/15/18 mg/kg Day 7: IL-1β ↑ Zhu, et al.
single i.p. Balb/c myofibrillar disorganization ↑ 2011
5 mg/kg / week x 5 i.p. Week 5: Pgc-1α, Pgc-1β ↑ Zhang, et al.
129/SvJae ROS level, fibrosis ↑ 2012
3 mg/kg / week x 4 i.p. Week 4: BW, HW, HW/BW ↓ Chen et al. 
Male Balb/c ROS level ↑ 2015
15 mg/kg single i.p. Day 6: FS ↓ LVmass/BW ↑ Ge et al. 
FWB LVEDD, LVESD ↑ SERCA2a, PGC-1α ↓ 2016
6 mg/kg single i.p. Day 10/20: N: EF n.s. Guenancia, 
Male C57BL/6 OW: EF ↓ LVEDD ↑ et al. 2016
10 mg/kg D1+D4 i.p. Day 8: EF, FS ↓ ROS, apoptosis ↑ Liu, et al.
Male C57BL/6 LVIDs ↑ PGC-1α ↓ 2018
4 mg/kg / week x 3 i.p.
Male C57BL/6N Week 8: n.s.
Week 3: BW, HW ↓
Anp ↑
Matsumura 
et al. 2018
20 mg/kg single i.p.
C57BL/6J Day 7: EF, FS ↓
BW, HW/TL ↓
β-MHC, ANP ↑
Willis, et al.
2019
ANP: Atrial natriuretic peptide; BW: Body weight; BNP: Brain natriuretic peptide; EF: Ejection fraction; FS:
Fraction shortening; HW: Heart weight; IL-1β: Interleukin 1 beta; i.p.: Intraperitoneal; LVEDD: Left
ventricular end-diastolic diameter; LVESD: Left ventricular end-systolic diameter; LVIDd: Left ventricular
internal diameter in diastole; LVIDs: Left ventricular internal diameter in systole; LVmass: Left ventricular 
mass; LVpres: left ventricular pressure; α-MHC: Myosin heavy chain alpha; β-MHC: Myosin heavy chain 
beta; N: normal; n.s.: not significant; OW: overweight; PGC-1α: Peroxisome proliferator activated receptor
gamma coactivator 1 alpha; PGC-1β: Peroxisome proliferator activated receptor gamma coactivator 1 
beta; ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor alpha.
26
 
 
  
  
 
    
    
       
      
   
  
      
  
 
  
          
     
      
       
    
    
    
  
    
      
      
  
     
       
         
     
  
     
     
   
 
     
 
 
Review of the Literature
2.5 Obesity and type 2 diabetes
2.5.1 General introduction
Overweight and obesity, conditions which influence harmfully on human health 
throughout the world, have reached a global epidemic scale as over one billion 
people worldwide are overweight (body mass index; BMI between 25 and 
29.9 kg/m2) or obese (BMI over 30 kg/m2) (Singh, et al. 2018, Carbone, et al. 2020). 
This is alarming as obesity increases the risk of cardiovascular and metabolic
diseases (Carbone, et al. 2020). Obesity may lead to hypertension, diabetes, HF, and
major cardiovascular events (De Lorenzo, et al. 2019). According to the World 
Health Organization, in 2016, a significant proportion i.e. 39% of adults aged 18
years and over, were overweight, and 13% were obese (https://www.who.int/news-
room/fact-sheets/detail/obesity-and-overweight, accessed April 26, 2020). The link 
between obesity and HF is notable, as depending on the demographics of the study,
the proportion of HF patients being overweight or obese tends to be rather high, with
percentages reaching 40% and 49%, respectively (Zhai & Haddad 2017, Horwich, 
et al. 2018). Obesity and metabolic syndrome are HFpEF-associated pathologies as
the prevalence of overweight and obesity is over 80% in HF patients with HFpEF
(Reddy & Borlaug 2016, Horwich, et al. 2018). Nonetheless, the overweight and
mild to moderate obese patients diagnosed with HF may exhibit considerably
improved survival as compared to normal weight patients (Horwich, et al. 2018). 
This phenomenon called the obesity paradox still remains unresolved though the
increased lean mass and higher cardiorespiratory fitness in obese individuals may
play a role in their improved prognosis of HF (Carbone, et al. 2020). Moreover, one
explanation might be that obese patients are diagnosed earlier in life, thus explaining
the improved prognosis (Turer, et al. 2012, Elagizi, et al. 2018). 
Obesity associates strongly with the development of type 2 diabetes (T2D)
(Zhai & Haddad 2017). The prevalence of T2D is increasing universally e.g. it has 
doubled over the last two decades driven by the obesity epidemic (Bugger & Abel
2014, Athithan, et al. 2019). T2D is now recognized as a global pandemic as it is 
included into the top ten causes of mortality and morbidity and in global terms, it 
represents a major medical and economic burden on the health services (Singh, et al.
2018, Athithan, et al. 2019). T2D accounts for 90-95% of all diabetes mellitus cases 
and it is a multifactorial metabolic disorder characterized by insulin resistance,
impaired insulin secretion and elevated hepatic glucose production and release 
leading to chronic hyperglycemia (Singh, et al. 2018, Athithan, et al. 2019, Kenny 
& Abel 2019).
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In numerous studies, diabetes has been shown to be a cardiovascular risk factor,
with the cardiovascular complications representing the major cause of mortality and 
morbidity in diabetic patients (Bugger & Abel 2014). Diabetes accelerates
atherosclerosis leading to coronary artery disease, and additionally evokes
deleterious effects on the heart. The structural, functional and metabolic myocardial 
changes may lead to HF, which is the most common cardiovascular complication
encountered in diabetes (Singh, et al. 2018, Athithan, et al. 2019, Evangelista, et al.
2019). The exact association of diabetes and HF is rather unclear but the relationship
is bidirectional as it leads to an increased HF risk for diabetes patients and,
conversely, diabetes worsens the HF outcome (Evangelista, et al. 2019). 
The Framingham study, started in 1974, was the first to identify the role of diabetes 
in HF; the risk of HF in diabetes patients was found to increase by twofold in men
and by fivefold in women compared with age-matched controls (Kannel, et al. 1974). 
In the general population, the prevalence of diabetes is 10-15% whereas in 
hospitalized HF patients, the prevalence rises up to 44%, (Evangelista, et al. 2019, 
Kenny & Abel 2019).
2.5.2 Pathological role of obesity and type 2 diabetes in the
heart
The precise mechanisms by which obesity induces HF are not entirely understood.
Nevertheless, it is known that a western diet can further contribute to the activation
of proinflammatory pathways, and obesity is also associated with alterations in 
hemodynamics, cardiac structure and neurohumoral regulation (Abel, et al. 2008, 
Carbone, et al. 2019). The obesity driven changes in the heart include left ventricle
dilation, remodeling and hypertrophy, and furthermore, increased left ventricular
end-diastolic pressure, right atrial pressure and pulmonary wedge pressure (Fig. 4)
(Abel, et al. 2008, Lavie, et al. 2018, Carbone, et al. 2019). Moreover, weight gain 
is connected with increased blood pressure, resulting in arterial hypertension, which
is a leading cause of HF (Carbone, et al. 2019). In obesity, increased SNS activity is
a key mechanism for hypertension. Furthermore, suppressed parasympathetic
activity is also associated with hypertension, and accounts for the elevated HR in
obese humans (Hall, et al. 2015). In addition, obesity promotes insulin resistance, 
subsequently evolving into hyperglycemia (Turer, et al. 2012, Zhai & Haddad 2017).
The diabetes-associated changes in myocardial structure and function, called
diabetic cardiomyopathy, were identified in 1972 (Rubler, et al. 1972). Diabetic 
cardiomyopathy has been recently defined by AHA (the American Heart
Association), ESC (the European Society of Cardiology) and EASD (the European 
Association for the Study of Diabetes) as a clinical condition of ventricular
dysfunction that occurs in the absence of coronary atherosclerosis and hypertension
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in patients with diabetes (Evangelista, et al. 2019). At present, diabetic
cardiomyopathy is considered as a progressive condition from an asymptomatic
subclinical period advancing via hypertrophy to diastolic dysfunction, and finally to
systolic dysfunction (Athithan, et al. 2019, Murtaza, et al. 2019). The diabetes-
associated changes interfering with the heart and impairing cardiac function include
altered lipid metabolism creating lipotoxicity, hyperglycemia, increased oxidative
stress, mitochondrial disturbance, endothelial dysfunction, fibrosis, and increased 
stiffness (Fig. 4) (Poornima, et al. 2006, Abel, et al. 2008, Turer, et al. 2012, Bugger
& Abel 2014, Singh, et al. 2018, Athithan, et al. 2019, Evangelista, et al. 2019). 
There is accumulating information that malfunctions in metabolic pathways play a
role in developing diabetic cardimyopathy. Previous studies have revealed the role
of calcium homeostasis as a relevant factor in diabetic cardiomyopathy, with data 
pointing to reduced SERCA2a expression, increased PLN expression, and ryanodine
receptor defects leading to elevated resting Ca2+ levels in cytosol, and diastolic
dysfunction (Fig. 4) (Poornima, et al. 2006, Pereira, et al. 2014, Singh, et al. 2018, 
Dillmann 2019). An excess of glycolytic intermediates, related to diabetic
cardiomyopathy, has been shown to reduce SERCA2a expression (Young, et al.
2002). In addition, acute hyperglycemia may be responsible for diastolic Ca2+ 
leakage from sarcoplasmic reticulum in cardiomyocytes via RyR2 (Pereira, et al.
2014). Furthermore, in diabetes patients, oxidative damage impacting on the heart 
impairs the vulnerable RyR channels (Murtaza, et al. 2019). A recent review raises
the phosphorylation of RyR2 and the subsequent increase of sarcoplasmic reticulum
Ca2+ leakage as the main disturbance of Ca2+ handling in the prediabetic heart
(Federico, et al. 2019). In the CUPID trial (introduced in section 2.2.1.2), almost half
of the patients had diabetes, highlighting the connection between HF and diabetes, 
and the relevance of calcium signaling (Dillmann 2019).
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Figure 4. The effects of obesity and type 2 diabetes on the heart. Obesity and type 2 diabetes
cause various detrimental changes impairing the heart including hypertension, 
lipotoxicity, hyperglycemia, oxidative stress, disturbances in mitochondria and calcium
cycling, remodeling of the left ventricle and increased stiffness followed from increased
fibrosis and endothelial dysfunction.
2.5.3 The models of obesity and type 2 diabetes
Obesity and T2D are most often studied using a mouse model of diet-induced obesity
(DIO) or using monogenic mice, commonly ob/ob mice (Fuchs, et al. 2018). The
ob/ob mouse model harbors a mutation in the leptin gene, resulting in a non-
functional protein and hypoleptinemic mice have a nearly 3-fold higher weight than 
a normal mouse (da Silva Xavier & Hodson 2018). The ob/ob mouse model has 
played an important role in unraveling the key position of leptin in energy
homeostasis, although the relevance of this mouse model for human obesity is not
clear (da Silva Xavier & Hodson 2018). 
The DIO mice exhibit many features of gradually developing human obesity,
including the slowly advancing weight gain and the progression of insulin resistance
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(Kleinert, et al. 2018). The feeding of the mice for 1-20 weeks with high fat diet
(HFD) containing 40-60% of calories from fat seems to be the most widely used 
animal model for studying obesity (da Silva Xavier & Hodson 2018). Generally, 
male mice develop obesity in a shorter time and to a greater extent than female mice,
indicating that male mice are more prone to DIO (Kleinert, et al. 2018). As well as 
obesity, the DIO mice usually exhibit hypertension, hyperglycemia, and
hyperinsulinemia (da Silva Xavier & Hodson 2018). However, there is no single,
standardized diet utilized to induce obesity, and the variation in nutrient
compositions and energy densities, as well as the differences between separate
mouse strains, lead to phenotype differences in DIO models (Barrett, et al. 2016).
For example, the strain C57BL/6J is prone to develop severe obesity, elevated
adiposity, glucose intolerance and moderate insulin resistance while the C57BL/6N
mice have been found to develop hepatosteatosis, hyperglycaemia and hyper-
insulinaemia (Kleinert, et al. 2018).
To model a more progressed state of T2D, a low dose streptozotocin (STZ) can
be utilized as an additional stressor (Heydemann 2016). STZ is a cytotoxic glucose
analogue targeting primarily pancreatic β-cells, having a damaging effect on their
mitochondrial and genomic DNA; this eventually triggers a partial loss of β-cells,
resulting in decreased insulin secretion (da Silva Xavier & Hodson 2018, Kleinert, 
et al. 2018). A common method is to combine DIO with the administration of a low
dose STZ to recapitulate the transition from the pre-diabetic state to the actual state 
of T2D (Kleinert, et al. 2018).
Concerning cardiac effects, there are many discrepancies between different
studies as some investigators have identified cardiomyopathy after a relatively short
period of HFD whereas other do not report cardiomyopathy despite feeding HFD for
over 6 months (Heydemann 2016). The effects of HFD-fed DIO model and STZ-
induced T2D model on the mouse heart are summarized in Table 2.
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Table 2. Cardiotoxic effects on the heart of wild-type mice in diet-induced obesity and
streptozotocin-induced type 2 diabetic model.
Model Functional changes Other changes Reference
HFD 16 months
male C57BL/6 IVSs, LVPWs ↑
HW, HW/TL ↑
β-Mhc, Col I ↑
hypertrophy ↑
Calligaris, 
et al. 2013
HFD 20 weeks FS ↓ HW, HW/TL ↑ Liang, et al.
male FVB LVESD, LVEDD ↑ hypertrophy ↑ 2015
HFD 12 weeks
male C57BL/6J
EF, FS ↓
LVESD, LVEDD ↑ HW, HW/BW ↑
Zhang, Y., 
et al. 2015
HFD 5 months
4–6 wo C57BL/6 FS ↓
IL-6, TNFα ↑
fibrosis ↑
Cao, et al.
2016
HFD 30 weeks Bnp ↑ Lucas, et al.
9 mo C57BL/6 cell area, fibrosis ↑ 2016
HFD 36 weeks
6 wo male C57BL/6J
Week 51: Tnf-α, Tgf-β1 ↑ 
Mmp9, Col1a1 ↑
fibrosis ↑
Daltro, et al.
2017
HFD 12 weeks cell size ↓ fibrosis ↑ Hung, et al.
44 wo male C57BL/6J cell−cell spaces ↑ 2017
HFD 16 weeks
10 wo C57BL/6
EF, FS ↓
IVSs, LVPWs ↑
Anp, Bnp, Tnf-α, IL-6, IL-1β ↑ 
disorganized myofibers,
collagen deposition ↑
Wang, et al.
2017
HFD 12 weeks BW ↑ TNF-α, IL-10 ↑ Kondo, et al.
10 wo male CL57/B6 fibrosis ↑ 2018
HFD 16 weeks
(+ control viral injection)
C57BL/6J 
EF, FS ↓
LVESD, LVEDD ↑
BW ↑ Tgf-β1, Col I&III ↑
collagen deposition ↑
Li, et al.
2018
HFD 6 weeks STZ 80
mg/kg single i.p.
4 wo male C57BL/6
EF, FS ↓
LVESD, LVEDD ↑
HW, HW/BW ↑
TGF-β1, COL I&III ↑
hypertrophy, fibrosis ↑
Huang, 
et al. 2017
HFD 4w  40mg/kg 
STZ for 5d HFD 4w 8 w: BW ↓ Anp ↑ Zhang, et al.
Male Mm. castaneus hypertrophy, fibrosis ↑ 2018
4–6 wo
HFD 8 weeks STZ 
120 mg/kg single i.p.
8–10 wo male
EF ↓ HW/BW ↑Tnf-α, IL-1β ↑
Feng, et al.
2019
HFD 12 weeks STZ 
100 mg/kg single i.p.
HFD 12/24 weeks
8 wo male C57BL/6
EF, FS ↓
Anp ↑
TNF-α, PGC-1α, COL1A1 ↑
hypertrophy, fibrosis ↑
Sun, et al.
2020
ANP: Atrial natriuretic peptide; BNP: Brain natriuretic peptide; BW: Body weight; COL I: Collagen I;
COL1A1: Collagen 1A1; COL III: Collagen III; EF: Ejection fraction; FS: Fraction shortening; HW: Heart
weight; HFD: High fat diet; IL-1β: Interleukin 1 beta; IL-6: Interleukin 6; IL-10: Interleukin 10; i.p.:
Intraperitoneal; IVSs: Intraventricular septum in systole; LVEDD: Left ventricular end-diastolic diameter;
LVESD: Left ventricular end-systolic diameter; LVPWs: Left ventricular posterior wall in systole; MMP9:
Matrix metalloproteinase 9; β-MHC: Myosin heavy chain beta; PGC-1α: Peroxisome proliferator activated 
-receptor gamma coactivator 1α alpha; STZ: Streptozotocin; TL: Tibia length; TGF-β1: Transforming 
growth factor beta 1, TNF-α: Tumor necrosis factor alpha; wo: week old.
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2.6 Gene therapy
2.6.1 General introduction
The first attempts to treat patients with genetic disease using foreign DNA were 
recorded at the beginning of 1970s (Friedmann & Roblin 1972). By 1990, the
technological advances had enabled the cloning of disease-related genes and
efficient transfer of genes into mammalian cells, however, there were still no 
clinically useful applications for genetic modifications (Friedmann 1990). At the
turn of the millennium, clinical trials utilizing gene therapy typically were targeted
to treat common polygenic diseases such as cancer, atherosclerosis and Alzheimer’s 
disease, and, on the other hand to rare and well defined genetic disorders such as
cystic fibrosis and Duchenne muscular dystrophy (Selkirk 2004). By 2013, the field 
had developed with over 1800 approved gene therapy clinical trials (Wirth, et al.
2013), and according to the most recent data from September 2019, there were over
3000 registered clinical trials with the main indications being cancer, monogenic,
infectious and cardiovascular diseases (http://www.abedia.com/wiley/indications.
php, accessed April 10, 2020).
The methods to deliver transgene into the target tissue can be divided into non-
viral and viral approaches. Non-viral vectors, for example, plasmid DNA, may 
enable high organ specificity, but they are able to achieve only a relatively low
transduction efficiency and short-lasting gene expression (Muller, et al. 2007). Viral
vectors are capable of a much more efficient delivery of the transgene, however, the
immunogenic response limits the feasibility of adenovirus and adeno-associated
virus (AAV) as approximately 97% of the population carry neutralizing antibodies
against adenoviral vectors and against AAV the proportion is up to 40% (Muller, 
et al. 2007, Tilemann, et al. 2012). Due to neutralizing antibodies, adenoviral gene
therapy has been demonstrated to lack long-lasting efficacy (Bradshaw & Baker
2013). The AAV vector has been shown to be safe, well-tolerated, longer lasting and 
less immunogenic than the adenovirus, although the host immune system may still
be triggered (Naso, et al. 2017). Retroviruses, integrating the transgene complex into
the host genome are capable of offering a lifetime expression of the transgene, but
with the cost of a potential for insertional mutagenesis. The development of safer, 
lentiviral vectors has reduced the risk of insertional mutagenesis (Hayward, et al.
2015, High & Roncarolo 2019). The triggering of guaranteed long-term transgene 
expression and the lack of neutralizing antibodies make lentivirus an appealing 
vector choice (Tilemann, et al. 2012). Recently, two clinical trials, utilizing
lentivirus reported the safety and benefits of lentiviral gene therapy, and the use of
lentiviral vectors seems to be increasing (Hayward, et al. 2015). In 2019, adenovirus,
AAV, retrovirus, and lentivirus together accounted for approximately 54% of gene
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therapy trials while naked plasmid were being utilized in 15% of trials
(http://www.abedia.com/wiley/vectors.php, accessed April 10, 2020). In the future, 
the creation of a gene transfer vector, which would enable the regulation of the
transgene expression in a fine tuned manner by an external stimulus, would be a
significant advance (Yla-Herttuala & Baker 2017). 
The process of developing more efficient and safer vectors for gene transfer is a 
complex path and the utilization of preclinical animal models is one of the crucial
steps towards success in clinical trials. Gene therapy is an area holding great promise,
yet clinical trials have so far failed to provide large scale consistent results and the
cost of successful therapies has been high (Yla-Herttuala 2017a, Gabisonia &
Recchia 2018). Several clinical gene therapy trials have displayed promising results,
including β-thalassemia in 2010, X-linked severe combined immunodeficiency
(SCID-X1) in 2010, and hemophilia B in 2011 (Wirth, et al. 2013). In recent years,
there have been some real success stories emerging from the clinical trials. In 2012, 
the first gene therapy product, AAV directed to lipoprotein lipase deficiency, was
approved by EMA (the European Medicines Agency), followed by e.g. retroviral
ex vivo gene therapy for adenosine deaminase-deficient SCID in 2016 and AAV
directed to retinal dystrophy in 2018 (Yla-Herttuala & Baker 2017, High &
Roncarolo 2019). 
2.6.2 Cardiac gene therapy
Although there have been significant developments in the field of treating HF with 
pharmacological drugs, nevertheless, current treatment methods are clearly not
sufficient (Wolfram & Donahue 2013, Shareef, et al. 2014). At the end of the 20th 
century, gene therapy became viewed as an intriguing prospective future method for
treating HF (Chien, et al. 1997, Hajjar, et al. 2000). Since then, the prospects to 
employ gene therapy in the cardiovascular field have been extensively studied.
Finally, during the recent five years, significant conceptual progress has been 
achieved as well in this field of gene therapy (Yla-Herttuala & Baker 2017).
The choice which vector to administer in cardiac gene therapy is important;
besides adenovirus and AAV, lentivirus may represent an applicable option, as 
cardiomyocytes are virtually nonproliferative, limiting the safety risk posed by
potential oncogenic transformation (Tilemann, et al. 2012). However, lentivirus has 
been reported to have a low cardiac transduction efficiency as compared to 
adenovirus and AAV, but on the other hand, lentivirus did not affect negatively
cardiac function, whereas adenovirus led to dilatation and systolic dysfunction, and 
AAV led to diastolic dysfunction in mouse heart (Wolfram & Donahue 2013, 
Merentie, et al. 2016). 
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In vivo methods to deliver the gene therapy vector to the heart include an
antegrade intracoronary infusion, an antegrade infusion with coronary artery balloon 
occlusion, a closed loop recirculation method, retrograde infusion through the
coronary sinus, pericardial injection, and direct myocardial injection (Hayward, 
et al. 2015, Ishikawa, et al. 2018). Antegrade coronary artery infusion is considered
to be a safe percutaneous gene delivery method and the recent gene therapy trials
have used this route to deliver the viral vectors, but unfortunately, the viral 
transduction efficacy has been shown to be limited (Shareef, et al. 2014, Hayward, 
et al. 2015). Direct intramyocardial injection results in a high local concentration of
the viral vector owing to an endothelial bypass, and allows minimal distribution of 
vector to off-target organs (Shareef, et al. 2014). However, with intramyocardial
injection, the coverage of areas that can be reached by injection is limited in human 
patients (Ishikawa, et al. 2018). The needle track may cover 1/8 of the left ventricular 
wall in mouse, but only 1/200 of the human ventricular wall (Yla-Herttuala 2017b). 
In the human heart, the best transduction efficiency achieved with any given method
is typically 10%-20% (Yla-Herttuala & Baker 2017). A peripheral intravenous
injection and a vector selectively transducing only cardiomyocytes would be an ideal
delivery choice, but it is a complicated equation in humans as their large blood 
volume causes a dilutional effect and, in addition, viruses may infect non-target
organs (Hayward, et al. 2015). In general, regarding large animals, the greater 
transgene efficiency is associated with higher invasiveness, and therefore the balance 
between the efficacy and the safety needs to be considered depending on the gene of
the interest, the patient population, and the desired transgene distribution (Ishikawa, 
et al. 2018).
In a recent review, Ylä-Herttuala discussed an important topic – pharmacological
aspects in gene therapy. Low dose or inefficient delivery to the target cells may cause
a failure. Beyond the classical ADME (Absorption, Distribution, Metabolism,
Excretion) parameters, in gene therapy, STED (Spreading through and reaching
appropriate cells in the target tissue, Transduction efficiency, Expression strength in
the transduced cells, Duration of gene expression) parameters may be more useful in
optimizing the therapeutic response (Yla-Herttuala 2017b). Furthermore, the 
translation from animal models to clinical trials may be challenging due to simpler
preclinical models with quantifiable endpoints for therapeutic response, compared 
to more variable disease process with functional and, additionally, subjective goals 
for improvement in clinical trials (Lahteenvuo & Yla-Herttuala 2017). Moreover, 
the restoration of myocardial force and contractility is a feasible target in patients 
with the early stage of HF, however, in more severe HF conditions, increased
fibrosis, apoptosis and arrhythmias pose severe difficulties for any therapy to cure
(Yla-Herttuala & Baker 2017). 
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Today, there are still many issues to be resolved, including physiologic target
validation of the myocyte, optimal strategies for gene target manipulation, vector
selection, correct vector dose, as well as an efficient and safe delivery route suitable
for the clinic, before gene therapy will be ready to be implemented (Fargnoli, et al.
2017, Ishikawa, et al. 2018). One innovation is to target gene therapy precisely to
the most appropriate areas of myocardium using electromechanical mapping
together with radiowater positron emission tomography (PET) imaging, a method
called NOGA mapping (Hassinen, et al. 2016). So far, the majority of gene therapy
trials have aimed at increasing blood flow to ischaemic tissue by therapeutic
angiogenesis e.g. utilizing vascular endothelial growth factor (VEGF), and fibroblast
growth factor (FGF), however, research interest has broadened from solely protein-
coding genes towards oligonucleotides and RNA regulation, especially in the field
of vascular therapy (Lahteenvuo & Yla-Herttuala 2017, Yla-Herttuala & Baker
2017). In the future, gene therapy is anticipated to represent a new horizon for, inter
alia, myocardial protection, repair and regeneration (Ginn, et al. 2018). It is unclear
whether the clinical trials have failed because of technical problems or because of
failures in the pharmacological properties of transgene products (Yla-Herttuala & 
Baker 2017). However, after some struggles in the past, there have been also
successes in clinical trials in the cardiovascular field. A trial utilizing an adenoviral
NOGA-mediated intramyocardial gene transfer of VEGF reported safe and well-
tolerated gene transfer and increased myocardial perfusion in refractory angina 
patients (Hartikainen, et al. 2017). 
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3 Aims of the study
The aim of this thesis was to investigate selected mouse models of heart failure to 
gain a better understanding of the molecular and functional changes in pathological
processes of heart failure, focusing on calcium signaling and neuropeptide Y. The
experimental heart failure models studied were doxorubicin-induced cardiotoxicity, 
diet-induced obesity and type 2 diabetes. Furthermore, this thesis aimed at studying 
the potential of the lentiviral gene therapy vector as a way of enhancing the calcium
cycling in a model of heart failure.
The specific aims were:
1. To set up a doxorubicin-induced mouse model of heart failure.
2. To produce a lentiviral vector expressing SERCA2a, to confirm the 
expressed protein product, and to validate the in vivo integration of the
transgene carried by the gene delivery vector.
3. To evaluate the therapeutic potential of the SERCA2a-expressing
lentiviral vector in the doxorubicin-induced heart failure model.
4. To study the effects of transgenic neuropeptide Y overexpression in the
doxorubicin-induced heart failure model.
5. To assess the effects of transgenic neuropeptide Y overexpression in the
diet-induced obesity and type 2 diabetes model.
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4 Materials and Methods
4.1 Animals
Male C57BL/6N WT mice (Harlan, Horst, The Netherlands) were used in Study I. 
Male homozygous transgenic OE-NPYDβH from homozygous breeders, and WT
mice from WT breeders originating from the same heterozygous breedings
maintained on a C57BL/6N inbred background were used in Studies II and III. Mice
were housed in the Central Animal Laboratory of University of Turku, individually 
in a ventilated cage system (Scanbur, Karlslunde, Denmark) at 22±1°C (Studies I &
II) or group-housed at 21±3ºC (Study III), under a fixed 12:12 h dark/light cycle with
free access to water ad libitum and regular chow feed (irradiated standard pellets)
unless stated otherwise in the dietary in vivo intervention of Study III (see section
4.2.1.3). 
4.1.1 Ethical aspects
Animal care was in accordance with the guidelines of the International Council of
Laboratory Animal Science (ICLAS). The experimental procedures were approved
by the National Animal Experimental Board (Eläinkoelautakunta, ELLA). The
studies were designed and performed according to ethical 3R’s (Reduction,
Replacement, Refinement) principles. The sample size was minimized to a number
of mice sufficient to detect statistically significant and physiologically relevant
differences. Excessive stress and suffering of the mice were avoided and the welfare
of the mice was monitored during the experiments via their weight gain, food intake
and visual condition. Any mice showing signs of serious illness were removed from
the study.
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4.2 In vivo interventions
4.2.1 Heart failure models
4.2.1.1 DOX-induced heart failure model (I & II)
Cardiac toxicity was induced by doxorubicin (Caelyx 2 mg/ml; Janssen
Pharmaceutica NV, Geel, Belgium) which was administered to mice as a single
intraperitoneal injection at a dose of 20 mg/kg. The well-being of the mice was
monitored carefully after DOX injection. The protocol to induce cardiotoxicity by 
DOX was based on earlier comparable studies (Nozaki, et al. 2004, Li, et al. 2006, 
Neilan, et al. 2006). Cardiotoxicity was assessed by monitoring weight, body
composition, gene and protein expression, and by echocardiography.
4.2.1.2 OE-NPYDβH transgene model (II & III)
The generation of the transgenic OE-NPYDBH mouse model has been described in 
detail by Ruohonen et al. (2008) and Vähätalo et al. (2015). This mouse model
overexpresses NPY in noradrenergic neurons in the brain and also in the peripheral
sympathetic nerves via the dopamine-beta-hydroxylase (DβH) gene promoter. 
OE-NPYDBH mice has been shown to exhibit increased fat mass and body weight,
which cause impairments of glucose metabolism and hyperinsulinaemia with age
(Vähätalo, et al. 2015). To verify that the current cohorts resampled the previously 
published cohorts, body weight, body composition (Studies II & III) and blood 
glucose measured with a glucose meter (Precision Xtra Glucose Monitoring Device,
Abbott Diabetes Care, Abbot Park, IL, USA) (Study III) were used as markers of the
metabolic phenotype.
4.2.1.3 Diet-induced obesity and type 2 diabetes models (III)
For DIO, mice were placed on high caloric Western type diet (WD) containing 40% 
kcal fat, 43% kcal carbohydrate, 17% kcal protein (D12079B, Research Diets, New
Brunswick, NJ, USA) for 12–15 weeks. To induce type 2 diabetes (i.e. insulin 
resistance and hypoinsulinemia), WD-fed mice were administered low-dose of STZ
intraperitoneally (40 mg/kg in 7.5 mg/ml Na-Citrate solution, pH 4.5, Sigma-
Aldrich, St. Louis, MO, USA) for 3 consecutive days. A single dose of STZ was re-
administered every 4.5 weeks to maintain hyperglycemia (Gilbert, et al. 2011). 
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4.2.2 Lentiviral vectors (I)
4.2.2.1 Generation and analysis of lentiviral vectors (I)
The human SERCA2a gene and green fluorescent protein (GFP) reporter gene
containing lentiviral vector (LV-SERCA2a-GFP) and the control vector containing
GFP gene (LV-GFP) were constructed. The human SERCA2a cDNA was subcloned 
into a bicistronic pWPI plasmid (Tronolab, Écolé Polytechnique Fédérale de
Lausanne, Switzerland) allowing simultaneous expression of the SEFCA2a gene and 
the GFP gene. Subsequently, the lentiviral construct plasmid pWPI, the packaging 
plasmid pR8.91, and the envelope coding plasmid pMD2G were co-transfected by
using the calcium phosphate protocol into human embryonic kidney 293T
(HEK293T) cells cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10 % fetal bovine serum, 2 mM L-glutamine, non-essential amino acids and
100 U/ml penicillin/streptomycin. The cells were incubated at 37°C with 5% CO2. 
Supernatant containing viral particles were harvested at 24 and 48 h after
transfection, centrifuged at 2300 g for 5 min at 4°C, filtered through a 0.45 μm filter
(Millipore, Bedford, MA, USA) and concentrated using ultracentrifugation settings
of 130000 g for 2 h at 4°C. The viral pellet was resuspended in cold phosphate-
buffered saline (PBS) (Sigma-Aldrich, St Louis, MO, USA) and stored frozen at
-150°C. The viral vector titers (transducing units/ml, TU/ml) were analyzed by flow
cytometry based on the relative amounts of infected, GFP-expressing cells in a 
diluted series of transduction on HEK293T cells. The cells were fixed for 15 min in
4% paraformaldehyde. The flow cytometry analysis was performed at the Turku
Centre for Biotechnology Cell Imaging Core facility on a LSRII machine using 
Cyflogic FACS analysis software (CyFlo Ltd, Turku, Finland).
4.2.2.2 Lentiviral injection (I)
Prior to the lentivirus injection, mice were anesthetized by inhalation of 4.5%
isoflurane with anaesthesia maintained by 1.5% isoflurane. The mice were 
immobilized on a warm plate, and HR, respiration rate and body temperature were
monitored. The intramyocardial injections were performed via 30-gauge needle 
using a 50-μl syringe (Hamilton, Reno, NV, USA) and micromanipulator
(VisualSonics, Toronto, Canada). Injections were visualized by ultrasound and
documented as video clips. A total volume of 30 μl (3 × 10 μl) was injected at a dose
of LV-SERCA2a-GFP 1.39×108 TU/ml and LV-GFP 9.18×108 TU/ml to three
distinct areas in the anterior wall of the left ventricle. Saline injection was performed
as a sham control procedure. 
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Materials and Methods
4.3 In vivo and ex vivo methods
4.3.1 Body composition (II & III)
Body composition (fat and lean mass) was measured with an EchoMRI-700 
quantitative nuclear magnetic resonance (qNMR) whole body composition analyzer
(Echo Medical Systems, Houston, TX) from conscious mice. Each animal was
scanned twice in order to minimize the error caused by the minor movements of the
animal. Average values for fat mass and lean mass, and fat and lean mass percentage 
relative to body weight were calculated from two separate scans. The weight of the 
mice was recorded once a week during the study.
4.3.2 Echocardiography (I–III)
Echocardiography was performed with the VisualSonics Vevo 2100 ultrasound 
system (VisualSonics, Toronto, Canada) equipped with a 30-MHz transducer. Mice 
were anesthetized by inhalation of 4.5% isoflurane. Anaesthesia was maintained by
1.5% isoflurane (Studies I & III) or by 1.5–2.5% isoflurane gating the HR between
400 and 500 beats per minute (Study II). Chemical hair remover (Veet; Reckitt 
Benckiser, Slough, UK) was rubbed onto the chests of the mice and gel (Eco
Supergel; Ceracarta, Forlì, Italy) was applied before the placement of the probe. The
mice were kept on a heating pad to maintain normothermia. HR, respiration rate and 
body temperature were monitored. Functional parameters and the dimensions of the
left ventricle, and HR were analyzed in a short-axis view (Studies II & III) and, 
additionally, in a parasternal long-axis view (Study I) using VisualSonics Vevo 2100
software version 1.2.0 (VisualSonics, Toronto, Canada).
4.3.3 Hemodynamic measurements (III)
The hemodynamic properties were studied in vivo in conscious freely moving mice
conducting carotid artery measurements via radiotelemetry as previously described
by Rinne et al. (2008). Briefly, mice were anesthetized with 2% isoflurane and a
polyethylene catheter was inserted into the left carotid artery and the transmitter
probe was positioned subcutaneously on the flank of the animal. Mean arterial
pressure (MAP) and HR were monitored. To assess the control of the autonomic
nervous system on the hemodynamics, the response to sympathetic activation was
studied by injecting mice with different doses of phenylephrine (PE, 2-32 µg/kg, i.v.)
and to study the parasympathetic activity, the anticholinergic drug, atropine, was
administered (2 mg/kg, i.p.). 
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4.3.4 Vascular reactivity analysis (III)
Wire micromyography was conducted ex vivo as previously described by Rinne
et al. (2013). Briefly, mouse thoracic aortae and small mesenteric arteries were
excised and arterial rings were mounted in a microvessel myograph for isometric
tension recording. When assessing vasoconstrictor responses, concentration-
response curves to PE were constructed. To invoke endothelium-dependent or
endothelium-independent relaxation, cumulative doses of either acetylcholine (ACh)
or sodium nitroprusside (SNP) were added to the chambers, respectively.
Vasorelaxation was studied in arterial rings precontracted with PE. The contribution 
of vasodilator nitric oxide (NO) to ACh-induced relaxation was determined by the
inhibitory effect of a nitric oxide synthase inhibitor L-NNA (100 μM). 
4.3.5 Tissue collection & sample preparation (I–III)
In Study I, the mice were sedated with CO2 before blood collection and sacrificed
by cervical dislocation. In Studies II and III, a terminal blood sample (0.5–1 ml) was 
collected by heart puncture or from the inferior vena cava. Prior to terminal blood 
sampling, the mice were anesthetized with inhaled isoflurane (induction 4.5%,
maintenance 1.5%) (Study II) or, after a 4 h fast, with ketamine (75 mg/kg i.p.
Ketaminol, Intervet Oy, Finland) combined with medetomidine (1 mg/kg i.p.
Cepetor, ScanVet Oy, Finland) (Study III).
In Study I, the hearts were snap-frozen in liquid nitrogen immediately after 
collection and stored at -70°C or fixed for 24 hours in 4% paraformaldehyde and
subsequently transferred to 70% ethanol and embedded in paraffin. In Study II, the
hearts were cut in half after which the apex of the heart was frozen in liquid nitrogen 
immediately after collection, stored at -70°C and used later for RNA extraction, and
the base of the heart was fixed for 24 hours in 4% paraformaldehyde and 
subsequently transferred to 70% ethanol and embedded in paraffin. In Study III, the 
hearts were halved and the apex of the heart was fixed for 24 hours in 10% formalin 
and subsequently transferred to 70% ethanol and embedded in paraffin. The base of
the heart was stored for 24 hours in 4°C RNA Stabilization Reagent (RNAlater,
Qiagen, Hilden, Germany) and subsequently transferred to -70°C. In addition, in
Study II, the tibia was collected and its length was recorded.
4.3.6 Histology (I–III)
The frozen sections (8 μm) were prepared and transferred onto Superfrost plus slides
(O. Kindler GmbH, Freiburg im Breisgau, Germany) and mounted (Study I) with
VectaShield Hard Set Mounting Medium with DAPI (Vector Laboratories, Inc.,
Burlingame, CA, USA). Paraffin sections (5 μm) were prepared and the sections
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Materials and Methods
were transferred onto Superfrost plus slides (O. Kindler GmbH, Germany). The
paraffin sections were stained with hematoxylin and eosin as well as with Van
Gieson’s staining. In Study I, the sections were photographed using a microscope 
(frozen sections: Axiovert 200M, Carl Zeiss, Oberkochen, Germany; paraffin
sections: BX60l, Olympus, Tokyo, Japan). In Study II, the sections were scanned
using a Pannoramic 250F Flash III SlideScanner (3dHistech, Hungary) and in Study
III using a Pannoramic 1000P slide scanner (3dHistech, Hungary). In Study I, the
myocardial wall thickness was measured from the paraffin sections by assessing
eight measuring points in the left ventricle. In addition, the sections were evaluated 
for tissue damage by a pathologist. In Studies II and III, myocardial degeneration,
inflammation, fibrosis and nuclear atypia were analyzed and scored by two 
observers, a pathologist and the primary investigator. Histological scoring was
carried out blinded as to the other investigator and to the treatment status of the mice.
Myocardial degeneration, inflammation, fibrosis and nuclear atypia were scored on 
a scale from 0 to 3. In case of discrepancy, the investigators evaluated the samples
together to gain consensus.
4.4 In vivo study design
The protocols for Studies I-III are described in Fig. 5. In Study I, DOX (n=14) or 
PBS (n=6) was administered to 9–11 week old WT mice as a single intraperitoneal
injection. The mice were sacrificed on day 28 and the serum and the hearts were
collected for analysis. For the gene transfer experiment, DOX was administered to
9–11 week old WT mice as a single intraperitoneal injection and the subsequent
intramyocardial lentiviral injections (LV-SERCA2a-GFP/LV-GFP) or PBS
(n=7/group) were performed under echocardiography surveillance two days later.
The mice were weighed weekly, and echocardiography control was conducted and 
the mice were sacrificed 6 weeks after intramyocardial injection. 
In Study II, DOX or saline was administered to 8–10 week old OE-NPYDβH and 
WT mice (n =7–9/group) as a single intraperitoneal injection. The mice were
weighed weekly, and the body composition of the mice was measured on week 0 and 
6 by qNMR. On week 6, cardiac structure and function were analyzed by 
echocardiography and the mice were sacrificed.
In Study III, OE-NPYDβH and WT mice were fed either with a chow diet (lean 
state) or with WD. To induce DIO or T2D, mice were fed with WD for 14 weeks
starting at the age of 5 weeks, or for 16 weeks starting at age of 13 weeks,
respectively. To induce T2D, 3 weeks after starting the WD, mice were administered
STZ on 3 consecutive days and a single dose of STZ was re-administered every 4.5
weeks to maintain hyperglycemia. The mice were weighed weekly and the body
composition was measured with qNMR at 9 weeks of age in lean state mice, and in
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DIO mice, 5 and 11 weeks after induction of DIO (at 10 and 16 weeks of age).
Echocardiography was conducted at the age of 18 weeks for both the lean and DIO
state mice. 24 hour urine samples were collected in metabolic cages at the age of 19
weeks. The vascular reactivity was measured ex vivo by wire myography in lean and
DIO mice (age 20 weeks, n=9–10/group). In addition, a cohort of T2D mice was
included in wire myography (n=7/group), and their blood vessels were collected at
13 weeks after the induction of hyperglycemia. The hemodynamic properties in lean
or DIO state were studied with a different cohort of mice utilizing radiotelemetry
and, in addition, using PE or atropine. 
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Figure 5. Experimental protocols of the interventions in Studies I-III. Wild-type (WT) mice (Studies 
I-III) and OE-NPYDβH (OE-NPY) mice (Studies II & III) were used. Mice were subjected 
to doxorubicin (DOX) in Studies I and II and to lentiviral injection in Study I. In Study III,
mice consumed normal chow diet or a Western Diet (WD) and, additionally, WD-fed 
mice were administered a low dose of streptozotocin (STZ). BP = Blood pressure,
HR = Heart rate, qNMR = Body composition measurement.
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4.5 Biochemical analyses
4.5.1 Brain natriuretic peptide assay (I)
In the measurement of brain natriuretic peptide (BNP) levels, the serum was 
separated from the blood sample with Capiject T-MG serum collection tubes 
(Terumo, Tokyo, Japan). The sample was incubated for 20 minutes at room
temperature prior to centrifugation (3000 g for 90 seconds). Serum was extracted
from the collection tube, frozen in liquid nitrogen and stored at -80°C. BNP levels 
were determined with Brain Natriuretic Peptide EIA Kit (Sigma-Aldrich, St Louis, 
MO, USA) adhering to the manufacturer’s instructions. 
4.5.2 Biochemical markers in the urine (III)
After 24 hour of habituation to metabolic cages, 24 hour urine samples were
collected. Noradrenaline was extracted with activated alumina and analyzed with
high performance liquid chromatography and coulometric electrochemical detection. 
NO metabolites levels in urine were measured with commercially available
colorimetric assay kit (Cayman Chemical, Ann Arbor, Michigan, USA).
4.5.3 Protein expression analysis (I)
HEK293T cells were infected with LV-SERCA2a-GFP lentiviral vector with a
multiplicity of infection (MOI) of 2, 5 and 10. After 48 hours, uninfected control
cells were counted (750 000 cell / well) and infected cells were lysed in a sample 
buffer. The samples were boiled for 5 minutes at 95°C and sodium dodecylsulfate-
polyacrylamide gel electrophoresis was performed with a 6% separating gel for 2
hour at 110 V. The run samples were transferred onto polyvinylidene fluoride
membranes by electroblotting for 1 hour at 400 mA. The membranes were blocked
with 5% milk in PBS-Tween 20 for 1 hour and incubated overnight at 4°C in 2.5 ml
of antibody working dilution (1 μl of Anti-SERCA2 ATPase Monoclonal Antibody,
clone IID8; Thermo Scientific, Waltham, MA, USA). Horseradish peroxidase
conjugated goat anti-mouse antibody 0.1 μg/ml working dilution (Dako, Glostrup,
Denmark) was added onto the membranes and incubated for 50 minutes at room
temperature. Light reaction was initiated by adding 4 ml of ECL mix (Pierce ECL
Western Blotting Substrate; Thermo Scientific, Massachusetts, USA) onto the
membranes which were then incubated for 2 minutes at RT, with X-ray film being
exposed to the light reaction in the dark.
Proteins were extracted from mice heart by disrupting the tissue in RIPA buffer 
(radioimmunoprecipitation assay buffer, supplemented with protease and
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Materials and Methods
phosphatase inhibitors cocktail) with Ultra-Turrax T25 Homogenizer (IKA®-Werke
GmbH & Co. KG, Germany), transferring the solution to a shaker at 250 rpm 4°C
for 1 hour and centrifuging 12 000 rpm 4°C for 20 minutes. Western blotting was
conducted as described above using a dilution of 1:1000 polyclonal anti-SERCA2a
antibody (sc-8095; Santa Cruz Biotechnology, Dallas, TX, USA) and a dilution of
1:10 000 horseradish peroxidase conjugated donkey anti-goat antibody. Actin was
probed with a dilution of 1:5000 anti-actin antibody (A2066; Sigma-Aldrich,
Missouri, USA) and a dilution of 1:20 000 horseradish peroxidase conjugated goat
anti-rabbit antibody dilution. The membranes were imaged with LAS-3000 Imager
(Fuji Photo Film Co., Tokyo, Japan). Images were quantified with ImageJ (National
Institutes of Health, Bethesda, MD, USA) and normalized to mean control values.
4.5.4 Gene expression analysis (I–III)
RNA was extracted from frozen heart tissue with RNeasy mini kit including DNase
treatment (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
The total RNA concentration and purity were determined with BioSpec-nano
Microvolume UV-Vis Spectrophotometer (Shimadzu Scientific Instruments
Columbia, MD, USA). Total RNA was transcribed to cDNA with High Capacity 
RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions. 
In Study I, reverse transcriptase polymerase chain reaction (PCR) was conducted
using Pfu polymerase enzyme with an annealing temperature of 58°C, running 35
cycles and visualizing the product in 2.5% agarose gel with ethidium bromide. The
list of the primers used in PCR analysis is presented in Table 3. In Studies II and III,
quantitative reverse transcriptase PCR (qPCR) was performed using the SYBR
Green method with Kapa Sybr Fast qPCR Kit (Kapa Biosystems, Woburn, MA, 
USA) and Applied Biosystems 7300 Real-Time PCR system according to the
manufacturer’s instructions for qPCR. Target gene expression was normalized to
housekeeping gene, ribosomal protein S29, expression and the fold induction was
calculated using the comparative ΔCt method and presented as relative transcript
levels (2-ΔΔCt). The list of the primers used in qPCR analysis is presented in
Table 3.
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Table 3. Primer sequences used in gene expression analyses.
Gene name Sequence Study
Adrenergic receptor, beta 1; Adrb1
(Beta1R) 
F: 5'-GTGGGTAACGTGCTGGTGAT -3'
R: 5'-GAAGTCCAGAGCTCGCAGAA-3' II
Atrial natriuretic peptide; Nppa (Anp) F: 5’-GCTTCCAGGCCATATTGGAG-3R: 5’-GGGGGCATGACCTCATCTT-3’ II
Brain natriuretic peptide; Nppb (Bnp) F: 5’-CTGAAGGTGCTGTCCCAGAT-3’R: 5’-CCTTGGTCCTTCAAGAGCTG-3’ II, III
Collagen I alpha 2; Col1a2 F: 5′-TGCAGTAACTTCGTGCCTAGC-3′R: 5′-ACGTGGTCCTCTGTCTCCA-3′ III
Green fluorescent protein; GFP F: 5′-GTTCAGCGTGTCCGGCGAGG-3′R: 5′-TCGGGGTAGCGGCTGAAGCA-3′ I
Interleukin 1 beta; Il1b (Il-1β) F: 5'-TGTAATGAAAGACGGCACACC-3'R: 5'-TCTTCTTTGGGTATTGCTTGG-3' II
Matrix metalloproteinase 2; Mmp2 F: 5’-GATGTCGCCCCTAAAACAGAC-3’R: 5’-CAGCCATAGAAAGTGTTCAGGT-3’ II
Matrix metalloproteinase 9; Mmp9 F: 5’-CTGGACAGCCAGACACTAAAG-3’R: 5’-CTGGCGGCAAGTCTTCAGAG-3’ II
Matrix metalloproteinase 13; Mmp13 F: 5’-ATCCCTTGATGCCATTACCA-3’R: 5’-AAGAGCTCAGCCTCAACCTG-3’ II
Myosin heavy chain alpha; Myh6
(Mhc-α)
F: 5’-CCACTTCTCCTTGGTCCACTATG-3’
R: 5’-ACAAACCCACCACCGTCTCA-3’ II
Myosin heavy chain beta; Myh7
(Mhc-β)
F: 5’-AGGGTGGCAAAGTCACTGCT-3’
R: 5’-CATCACCTGGTCCTCCTTCA-3’ II
Neuropeptide Y; Npy F: 5’-CTCCGCTCTGCGACACTAC-3’R: 5’-GGAAGGGTCTTCAAGCCTTGT-3’ II, III
Peroxisome proliferative activated
receptor gamma coactivator 1 alpha;
Ppargc1 (Pgc-1α) 
F: 5'-TATGGAGTGACATAGAGTGTGCT-3'
R: 5'-CCACTTCAATCCACCCAGAAAG-3' II, III
Phospholamban; Pln F: 5’-CACTGTGACGATCACCGAAG-3’R: 5’-CAGCATCTCGTTTCGCATTA-3’ II
Ribosomal protein S29; Rps29 (S29) F: 5’-ATGGGTCACCAGCAGCTCTA-3’R: 5’-AGCCTATGTCCTTCGCGTACT-3’ II, III
Ryanodine receptor 2; RyR2 F: 5’-CAGCATCTCGTTTCGCATTA-3’R: 5’-GGCTGTGTTCCACCTTCAAT-3’ II
Sarcoplasmic reticulum Ca2+ ATPase;
Atp2a2 (Serca2a)
F: 5′-GAGAACGCTCACACAAAGACC-3′
R: 5′-CAATTCGTTGGAGCCCCAT-3′ I
Serca2a F: 5’-GAGAACGCTCACACAAAGACC-3’R: 5’-CTTCTTCAGCCGGCAATTCGTTG-3’ II
SERCA2a (Human) F: 5′-GAACTCAACCCCTCCGCCCAGC-3′R: 5′-ATTGCCCGCCCCTCCTCAACG-3′ I
Smooth muscle actin alpha; Acta2
(α-Sma)
F: 5'-AGATTGTGCGCGACATCAAAG-3'
R: 5'-GCAGACTCCATACCGATAAAGGA-3' II
Transforming growth factor beta 1; 
Tgfb1 (Tgf-β1)
F: 5'-TGGAGCAACATGTGGAACTC-3'
R: 5'-CAGCAGCCGGTTACCAAG-3' II, III
Tumor necrosis factor alpha; Tnf
(Tnf-α) 
F: 5'-CTGAACTTCGGGGTGATCGG-3'
R: 5'-GGCTTGTCACTCGAATTTTGAGA-3' II
Tyrosine hydroxylase; Th F: 5’-CCCAAGGGCTTCAGAAGAG-3’R: 5’-GGGCATCCTCGATGAGACT-3’ II
NPY Y1 receptor; Npy1R F: 5'-TCACAGGCTGTCTTACACGACT-3'R: 5'-TTTCTCCTTTTCAAGCGAATG-3' II
NPY Y5 receptor; Npy5R F: 5'-CAGATTAATCCAGCTGTTCTGC-3'R: 5'-GAAAACAGCCTTTATTTGACAATG-3' II
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4.6 Statistical analyses
GraphPad Prism 6 software (La Jolla, USA) was used in the statistical analyses.
Statistical significance was accepted at the level of P < 0.05. Data are presented as
the mean of absolute values, or as the mean percentage change of parameters over
time ± standard error of the mean (SEM).
In Study I, normality of the populations and statistical significances were 
determined using the Kolmogorov–Smirnov test (a test which compares the observed 
distribution of two groups) or Student’s t-test, respectively. In Study II, statistical 
significances were determined with unpaired Student’s t-test, with two-way
ANOVA using NPY overexpression and DOX as independent variables, or with 
ANOVA for repeated measures. In two-way ANOVA, multiple comparisons were
analyzed and corrected with Bonferroni or Tukey post-hoc tests when the P-value
for interaction of genotype and treatment effect was < 0.1. In study III, statistical 
significances were determined with two-way ANOVA using NPY overexpression
and DIO as independent variables, with ANOVA for repeated measures, or with
Students t-test. In two-way ANOVA, multiple comparisons were analyzed and
corrected with Sidak or Bonferroni post-hoc test when the p-value for interaction of
the genotype and diet effect was < 0.1.
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5 Results and discussion
5.1 The effects of DOX-induced cardiotoxicity 
(Studies I & II)
5.1.1 Weight and body composition
In Study I, DOX decreased the weight of the WT mice (Fig. 6A, B). In Study II,
DOX treatment resulted in a milder response (Fig. 6C), nevertheless, weight gain
over time was significantly decreased in both WT and OE-NPYDβH mice (Fig. 6D),
and cumulative weight gain and fat mass gain were significantly decreased when the
genotypes were analyzed together (Fig. 6E, G). Lean mass gain was significantly
decreased by DOX only in the OE-NPYDβH mice (Fig. 6F). In addition, DOX
treatment tended to decrease the weight of the heart (P=0.061) and heart/tibia ratio 
(P=0.073) when the genotypes were analyzed together (Table 4). In summary, the
weight gain and fat mass gain were significantly hampered by DOX, which fits with
the previous results of studies using similar doses as in our experimental setting (15 
to 20 mg/kg) including both single and cumulative dosing regimens (Li, et al. 2006, 
Zhu, et al. 2010, Zhang, W., et al. 2015, Sahu, et al. 2016). The decreased heart
weight in relation to body weight or tibia length has been reported in several studies
(Li, et al. 2006, Zhu, et al. 2010, Chen, et al. 2015, Matsumura, et al. 2018). A 
possible cause for this might be impaired cardiac growth and cardiac atrophy 
(Matsumura, et al. 2018). The decreased weight gain after DOX treatment served as 
an indicator of a downturn in the general well-being of the mice.
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Figure 6. Body weight and composition in saline and doxorubicin (DOX) -treated mice. A) Body
weight over 4 weeks and B) body weight at week 4 in wild-type (WT) mice
(n=6-14/group). C) Body weight and D) weight gain change over 6 weeks, E) body 
weight gain, F) lean mass gain and G) fat mass gain at week 6 in WT and OE-NPYDβH 
(OE-NPY) mice (n =7–9/group). Values are presented as means ± SEM. A) *** P<0.001 
ANOVA for repeated measures, B) *** P<0.001 Student’s t-test, C) @ P<0.05, 
@@ P<0.01 OE-NPY DOX vs. OE-NPY saline with Bonferroni post-hoc test following
two-way ANOVA, D) # P<0.05, ** P<0.01, *** P<0.001 Tukey post-hoc test following
ANOVA for repeated measures, E),G) *** P<0.001 two-way ANOVA treatment effect,
E) ** P<0.01 two-way ANOVA genotype effect, F) ## P<0.01, *** P<0.001 Tukey post-
hoc test following two-way ANOVA.
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Table 4. Organ weights and tibia lengths of the saline and doxorubicin-treated wild-type and 
NPY-OEDβH mice.
WT saline OE-NPY saline WT DOX OE-NPY DOX
Heart (mg)
Lungs (mg)
Liver (g)
Tibia (mm)
Heart/Tibia
148.5 ± 6.2
138.1 ± 8.0
1.45 ± 0.12
17.6 ± 0.05
8.39 ± 0.39
147.7 ± 4.1
144.9 ± 3.9
1.57 ± 0.09
17.5 ± 0.09
8.44 ± 0.25
133.6 ± 3.1
154.3 ± 8.8
1.47 ± 0.06
17.6 ± 0.04
7.60 ± 0.16
142.9 ± 5.4
157.0 ± 7.0
1.47 ± 0.04
17.6 ± 0.02
8.11 ± 0.31
WT wild-type mice, OE-NPY neuropeptide Y overexpressive mice, saline saline treatment,
DOX doxorubicin treatment. Values are presented as mean ± SEM. Statistics were analyzed with 
two-way ANOVA (n=6-8/group). Reprinted with permission from Mattila et al. Journal of Gene 
Medicine, 2016:18,124–133.
5.1.2 Study I
5.1.2.1 SERCA2a protein expression
SERCA2a protein levels seemed to be lower in the hearts of the DOX-treated WT
mice compared to saline-treated control mice 4 weeks after DOX treatment, though
statistical significance was not reached (Fig. 7). Previous studies have addressed the
decrease of the SERCA2a protein expression subsequent to DOX treatment, and the
current result is in line with these previous findings, thus supporting in that respect
the cardiotoxicity generated in the current study setting (Ge, et al. 2016, Llach, et al.
2019).
Figure 7. SERCA2a protein levels adjusted to actin levels in doxorubicin-treated (DOX, n=11) or 
saline-treated (n=6) wild-type mice heart. Modified from publication I.
5.1.2.2 Histological analysis
The histological findings of the hearts were examined at 4 weeks after DOX
treatment in WT mice. Even though there were no statistically significant changes
between the DOX-treated and saline-treated mice, the increasing observable
degradation in myocardial tissue seen as lighter, more indistinctly defined area
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(signified with arrow) was found to follow the higher heart/weight and lower
SERCA2a/Actin protein ratio (unpublished data) (Fig. 8A–D). This suggests that
there had been differences in the DOX response between individual animals as the 
observations are pointing coherently to either milder or stronger degradation, heart
mass growth, and decrease in SERCA2a protein level. In previously published
literature, a decreased heart weight has been a common finding in response to DOX, 
but also increased heart weight (Ito, et al. 2009) and left ventricular mass (Ge, et al.
2016) have been reported (see Table 2 for review).
Figure 8. Examples of histological findings in the paraffin sections of the heart stained with
hematoxylin/eosin. A)–C) Doxorubicin-treated mouse exhibited degradation indicated
with arrow, D) saline-treated mouse with normal histological profile. H/W: heart mass /
body weight ratio, S2a/Act: SERCA2a/Actin protein level ratio. Scale bar indicates 
100 µm length.
5.1.3 Study II
5.1.3.1 Echocardiography analysis
Echocardiography was conducted six weeks after DOX administration in WT and 
NPY-OEDβH mice. DOX treatment tended to decrease ejection fraction (Fig. 9A) and 
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fractional shortening (Fig. 9B) when the genotypes were analyzed together. There 
were no differences in left ventricle internal diameter in diastole or systole or in
interventricular septum in systole and diastole (II: Fig. 2C–F). Moreover, DOX
tended to decrease the mass of the left ventricle when the genotypes were analyzed
together (Fig. 9C), corresponding to a change seen also in heart weight measured at
termination. The changes evident in the echocardiography analysis were quite
moderate; ejection fraction and fractional shortening tended to be decreased in the
DOX-treated mice. Previous studies have usually reported more markedly decreased
ejection fraction and/or decreased fractional shortening in comparable research
settings (Li 2006, Zhu 2010, Ge, 2016, Llach 2019). Nevertheless, these findings
support the larger picture of DOX-induced cardiotoxicity.
Figure 9. Echocardiography data in saline and doxorubicin (DOX) -treated wild-type (WT) and
OE-NPYDβH (OE-NPY) mice (n=7-8/group). A) Ejection fraction (EF), B) fractional
shortening (FS), C) left ventricle mass (LV mass). Values are presented as means ±
SEM. A)-C) P=0.056, P=0.050 two-way ANOVA treatment effect; P=0.084, P=0.086
DOX-treated OE-NPY vs. WT t-test; P=0.066 two-way ANOVA genotype effect.
Modified from publication II.
5.1.3.2 Histological analysis
The histological analysis was performed at 6 weeks after DOX treatment in WT and
OE-NPYDβH mice. Saline-treated hearts appeared to be histologically normal as no 
nuclear atypia, changes in nuclear size, fibrosis or perivascular inflammation were
observed (Fig. 10A, B). In DOX-treated hearts of either genotype, as an example of
abnormal findings, there were cytoplasmic degeneration of myocardial cells
(Fig. 10C, arrow), hypertrophy of the myocardial cell nuclei (Fig. 10D, arrow), some
extravasated red blood cells (Fig. 10C, asterisk) and mild fibrosis (Fig. 10E, arrow).
Even though the statistical significance was inconclusive, these findings are in 
agreement with previous reports of DOX treatment leading to cardiomyocyte
disorganization and myofibrillar loss (Arola, et al. 2000, Li, et al. 2006, Zhu, et al.
2010, Zhu, et al. 2011, Sahu, et al. 2016).
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Figure 10. Examples of histological findings in the paraffin sections of the heart stained with
hematoxylin/eosin and Van Gieson’s staining. A)-B) Saline-treated mouse with normal
histological profile, C)–E) doxorubicin-treated mouse. Arrows signify C) degeneration of
myocardial cells, D) hypertrophy of the myocardial cell nuclei E) mild fibrosis and
asterisk point C) extravasated red blood cells. Scale bar indicates 100 µm length.
Reprinted with permission from Mattila et al. Cardiovascular Toxicology, 2020; 20:
328–33.
5.1.3.3 Gene expression analysis
Genes modifying calcium cycling
Gene expression related to cardiac calcium cycling was studied 6 weeks after DOX
treatment in WT and NPY-OEDβH mice. DOX treatment resulted in significantly
lower Serca2a (Fig. 11A) and RyR2 (Fig. 11B) expression when the genotypes were 
analyzed together. These are well-described effects of DOX-induced cardiotoxicity 
on intracellular calcium metabolism and the present results parallel those reported
previously (Boucek, et al. 1999, Hanna, et al. 2014, Tocchetti, et al. 2014). Markedly 
decreased Serca2a and RyR2 expression levels represent strong molecular level
evidence of the disturbed calcium cycling in the present HF model. 
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Figure 11. Relative expression levels of genes modifying calcium cycling system in the heart of
saline and doxorubicin (DOX)-treated wild-type (WT) and OE-NPYDβH (OE-NPY) mice
(n = 5–8/group). A) Sarcoplasmic reticulum Ca2+ ATPase (Serca2a) level, B) ryanodine 
receptor 2 (RyR2) level. Values are presented as means ± SEM. * P<0.05 two-way
ANOVA treatment effect. Modified from publication II.
Marker genes of cardiomyopathy
Several genes involved in cardiomyopathy, inflammation, structural integrity and
fibrosis were studied. Atrial natriuretic peptide (Anp) expression levels were
significantly higher in DOX-treated mice when the genotypes were analyzed
together (Fig. 12A), though there were no differences in Bnp expression (Fig. 12B).
DOX altered also the expression of two genes involved in the degradation of
proteins; matrix metalloproteinase 2 (Mmp2) expression was increased (Fig. 12C)
and matrix metalloproteinase 9 (Mmp9) tended to be increased (Fig. 12D) by DOX
when the genotypes were analyzed together. There were no differences in the
expression levels of matrix metalloproteinase 13 (Mmp13) (Fig. 12E) or in those of
the measured cytokines including interleukin-1β (IL-1β), transforming growth factor
beta 1 (Tgf-β1) and tumor necrosis factor-α (Tnf-α) (Fig. 12F–H). With respect to
fibrosis, no significant changes were seen in the myofibroblast marker, α-smooth
muscle actin (α-Sma) (Fig. 12I).
Based on reports on animal models with the corresponding setup, DOX was
expected to upregulate both Anp and Bnp, as well as the marker genes of
inflammation and fibrosis (Prathumsap, et al. 2020). Furthermore, in previous
studies, DOX has been shown to upregulate matrix metalloproteinases, which 
participate in the degradation of sarcomeric and cytoskeletal proteins (Octavia, et al.
2012, Chen, et al. 2014, Tocchetti, et al. 2014, Polegato, et al. 2015). Here, the
changes in gene expression regarding the cardiomyopathy markers were rather
modest pointing to fairly mild cardiotoxicity. However, the increased Anp level 
indicates that the cellular mechanisms driving hypertrophy had been recruited and
the increase in Mmp2 expression points to activation of degradation of structural
proteins, with the changes being consistent with observations evident in human HF
(Meyer, et al. 1995, Polyakova, et al. 2011, Volpe, et al. 2014, Acsai, et al. 2016). 
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Figure 12. Relative expression levels of cardiomyopathy marker genes in the heart of saline and 
doxorubicin (DOX) -treated wild-type (WT) and OE-NPYDβH (OE-NPY) mice 
(n=5–8/ group). A) Atrial natriuretic peptide (Anp), B) B-type natriuretic peptide (Bnp), 
C) matrix metalloproteinase 2 (Mmp2), D) matrix metalloproteinase 9 (Mmp9), 
E) matrix metalloproteinase 13 (Mmp13) l, F) interleukin-1β (Il-1β), G) transforming
growth factor-β (Tgf-β), H) Tumor necrosis factor-α (Tnf-α), I) α-smooth muscle actin
(α-Sma) level. Values are presented as means ± SEM. * P<0.05, ** P<0.01, P=0.075
two-way ANOVA treatment effect. Modified from publication II.
Genes modifying sympathetic activity and mitochondrial biogenesis
The rate-limiting enzyme in noradrenaline synthesis, Th, tended to be increased by
DOX treatment when the genotypes were analyzed together (Fig. 13A), while there
were no differences in beta-1 adrenergic receptor expression, Beta1R (Fig. 13B) or
in mitochondrial biogenesis regulator peroxisome proliferator-activated receptor
gamma coactivator-1α (Pgc-1α) (Fig. 13C) expression. The higher expression of Th
suggested that cardiac SNS activity was increased in DOX-treated mice, which is 
consistent with previous studies reporting that DOX upregulates the TH protein level 
thus linking DOX-induced cardiomyopathy to increased SNS activity (Tong, et al.
1991, Bartoli, et al. 2011, Jin, et al. 2014). Beta1R has previously been shown to be
downregulated by DOX while in the current study there was no significant change
between the saline and DOX-treated animals (Jin, et al. 2014). Similarly, the
PGC-1α protein level has been previously shown to be decreased by DOX (Yin, 
57 
 
 
       
 
 
    
        
       
       
    
    
  
   
    
  
  
     
     
      
      
      
      
 
       
     
     
B C 
3.0 
p=0.065 
-~ 1.5 
C 2.0 
" ~ -~ ·~ !! [ 1.5 i 2.0 ?1,0 >< ., .. ., > -~ 1.0 ., ~ 
> ~ i; 1.0 e o.s 
! e: ~ 0.5 
~ s /, ., 
0.0 Ill 0 .0 
0, 
Q. 0.0 
Saline DOX 
Saline DOX Saline DOX 
Minttu Mattila
et al. 2018), but there was no change in the gene expression levels in the current
study.
Figure 13. Relative expression levels of the genes modifying sympathetic activity and mitochondrial
biogenesis in the heart of saline and doxorubicin (DOX) -treated wild-type (WT) and 
OE-NPYDβH (OE-NPY) mice (n=5-8/group). A) Tyrosine hydroxylase (Th) level,
B) beta-1 adrenergic receptor (Beta1R) level, C) peroxisome proliferator-activated
receptor gamma coactivator-1α (Pgc-1a) level. Values are presented as means ± SEM,
P=0.065 two-way ANOVA treatment effect. Modified from publication II.
5.1.4 Overview of DOX-induced cardiotoxicity
DOX significantly decreased weight gain and the expression level of the genes 
modifying calcium cycling, and increased the expression level of marker genes of
cardiomyopathy. In addition, some effects on heart weight, SERCA2a protein level
and histology were seen, even though statistical significance was inconclusive in 
those respects. With regard to the functional parameters of the heart, in study II, the 
response to DOX was rather mild, however, when the WT and OE-NPYDβH 
genotypes were analyzed together, there was a trend in the treatment effect
suggesting slight decrease in both EF and FS by DOX. The functional effects of
DOX in Study I were present and are discussed in the gene therapy section below
(see 5.2.3 Echocardiography analysis). Overall, DOX evoked less harsh response
than expected based on the previous literature, and instead of severe heart failure,
rather a state of cardiotoxicity was evident. As a part of the rationale behind Study I
was to examine if the detrimental effects of DOX on the function of the heart could
be overcome by viral gene therapy aimed at enhancing calcium cycling. 
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5.2 Lentiviral SERCA2a gene therapy (Study I)
5.2.1 The validity of lentiviral vector
5.2.1.1 SERCA2a protein expression analysis
The ability of lentiviral vector LV-SERCA2a-GFP to generate the correct SERCA2a
protein product was tested in HEK293T cells, which were infected with the
LV-SERCA2a-GFP lentiviral vector with a MOI 2, 5 and 10. The expression of
SERCA2a protein product (110 kDa) produced by the lentiviral vector was 
confirmed by Western blot analysis, demonstrating increased levels of SERCA2a
protein with higher MOIs (Fig. 14).
Figure 14. Western blot image of SERCA2a expression induced by LV-SERCA2a-GFP lentiviral
vector in human embryonic kidney 293T cells with multiplicity of infection 2, 5 and 10.
5.2.1.2 Validation of transgene integration
As the lentiviral vector used in this study integrates its transgenes into the host
genome, the integration of human SERCA2a gene and reporter gene GFP into mouse
heart was validated by reverse transcriptase PCR. The analysis showed transgene 
expression in LV-SERCA2a-GFP and LV-GFP injected hearts, confirming that the
human SERCA2a gene and the GFP gene had been successfully integrated into the
mouse genome after viral injections (Fig. 15). In addition, endogenous mouse
Serca2a levels were analyzed and there were no overt differences between the
groups. As a positive control, HEK293T cells were infected by LV-SERCA2a-GFP. 
The documented integration of the SERCA2a gene into the mouse genome provided
a solid base from which to initiate a study investigating the therapeutic effect of the
LV-SERCA2a-GFP virus vector in the DOX-induced HF model.
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Figure 15. SERCA2a and GFP gene integration into mouse heart. Reverse transcriptase PCR
analysis from LV-SERCA2a-GFP (LV-S2a-GFP), LV-GFP and saline (PBS) injected
mouse heart. PCR analysis from LV-SERCA2a-GFP transduced human embryonic
kidney 293T cells (HEK293T LV-S2a-GFP) are shown as a positive control. Reprinted
with permission from Mattila et al. Journal of Gene Medicine, 2016:18,124-133.
5.2.2 Lentiviral injection
In the SERCA2a gene therapy study, lentiviral vectors were injected into the anterior
wall of the hearts under ultrasound guidance. Intramyocardial injections were well
tolerated with no mice dying from the operation. The integration of the lentiviral
transgene into the mouse genome and the location of the infected area in the mouse
heart were determined by analyzing reporter protein GFP fluorescence from frozen
heart sections. Robust GFP expression in the LV-SERCA2a-GFP injected hearts was 
clearly distinguishable from the background (Fig. 16A, B; asterisk). As expected,
there was no GFP expression in the saline injected hearts (Fig. 16C).
As shown in figure 7, the SERCA2a protein level seemed to be reduced in 
response to DOX, and the rationale was to increase the SERCA2a level with
lentiviral gene transfer. Lentiviral gene therapy was successfully applied as the 
correct lentiviral SERCA2a protein product was confirmed, the transgene
integrations into the host genome were confirmed and the cardiac tissue was
confirmed to be transduced by the lentiviral vector. In a previous study, the human 
SERCA2 gene was successfully transferred lentivirally into the rat heart by 
intracoronary delivery, achieving a notable area of infected cells (Niwano, et al.
2008). In this study, the infected area in the anterior wall of the left ventricle was
moderate in size, stretching approximately 200 µm away from the needle track. 
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Figure 16. Frozen sections from intramyocardial injection of the LV-SERCA2a-GFP lentiviral vector
into the left ventricular wall of the mouse heart. A–B) LV-SERCA2a-GFP injected heart,
C) control heart injected with saline. Reporter protein GFP expression is indicated with
an asterisk and the needle track of intramyocardial injection is indicated with arrows.
Modified from publication I.
5.2.3 Echocardiography analysis
On the injection day (day 0), that is two days after DOX administration, there were
no differences in echocardiography parameters between the groups (Fig. 17A, C, E).
However, EF had already declined from the normal level, i.e. the level of the saline-
treated WT control mice in Study II, 60.2 ± 3.1% (n=8) (Fig. 9) or the control animals
in the similar studies (Riad, et al. 2008, Guenancia, et al. 2016). On day 28, absolute
EF values were significantly higher in LV-SERCA2a-GFP (SERCA2a) injected 
mice compared to control virus LV-GFP (GFP) injected mice or saline (PBS)
injected mice (Fig. 17A). From injection day to day 28, EF demonstrated a 
significant improvement in SERCA2a injected mice compared to GFP injected mice
(Fig. 17B) and there was a marked increase in both the changes in end-systolic
volume (ESV) and end-diastolic volume (EDV) change in the GFP and PBS injected
mice in comparison to SERCA2a injected mice (Fig. 17C, D, F). Thus SERCA2a
gene therapy enhanced notably the function of the heart and reduced left ventricular
dilatation as EF increased and ESV decreased, despite the compact viral transduction
area. Comparable results regarding changes in EF and cardiac volumes have been
obtained in previous SERCA2a gene therapy reports exploiting ischemic heart
failure models (del Monte, et al. 2001, Niwano, et al. 2008).
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Figure 17. Echocardiography analyses of LV-SERCA2a-GFP (SERCA2a; n=5), LV-GFP (GFP;
n=6) and saline (PBS; n=6) injected mice, treated with doxorubicin, on injection day (day
0) and on day 28. A) Ejection fraction (EF), B) EF percentual change from day 0 to day 
28, C) end-systolic volume (ESV), D) ESV percentual change from day 0 to day 28, E)
end-diastolic volume (EDV), F) EDV percentual change from day 0 to day 28. * P<0.05 
Kolmogorov-Smirnov test (SERCA2a vs GFP; SERCA2a vs PBS). Modified from
publication I.
5.2.4 Brain natriuretic peptide level in serum
Six weeks after DOX administration, the BNP levels seemed to be lowest in
LV-SERCA2a-GFP (SERCA2a) injected mice, followed by the saline (PBS) and
LV-GFP (GFP) injected mice (Fig. 18), although the differences were not
statistically significant. In a previous SERCA2a gene therapy study, the BNP level
was reported to decrease significantly after administration of the SERCA2a
62
 
 
       
  
 
       
     
  
           
       
   
   
      
    
 
 
        
    
    
  
\ 
) ": \ 
~ I =,=~ 
800 
600 
] 400 
~ 
200 
o.........__~_ 
SERCA2a GFP PBS 
B C 
Results and discussion
containing AAV vector (Kawase, et al. 2008) and the BNP levels in the current study
were comparable with that previous study.
Figure 18. Serum brain natriuretic peptide (BNP) levels in LV-SERCA2a-GFP (SERCA2a; n=5),
LV-GFP (GFP; n=6) and saline (PBS; n=6) treated mice. Modified from publication I.
5.2.5 Histological analysis
The paraffin sections of the hearts were measured 6 weeks after DOX treatment from
eight points in the left ventricle to analyze the myocardial wall thickness. The
analysis suggested that the average myocardium in LV-SERCA2a-GFP injected
heart (Fig. 18B) was thicker than that in the LV-GFP injected heart (Fig 18A) and 
resembled an untreated heart (Fig. 18C), although no definitive conclusions could be
drawn because of the small sample size. No differences in fibrosis or inflammation
were observed between treatment groups.
Figure 19. Histology images from hematoxylin and eosin stained paraffin sections of mouse heart.
A) LV-GFP injected heart, B) LV-SERCA2a-GFP injected heart, C) Normal untreated 
heart as a control (n=1/group). Reprinted with permission from Mattila et al. Journal of
Gene Medicine, 2016:18,124-133.
63 
 
 
  
 
    
      
       
     
   
 
    
   
 
  
  
     
    
     
 
      
   
 
  
    
     
     
   
     
       
     
     
       
     
Minttu Mattila
5.3 The effects of NPY overexpression on the
DOX-induced cardiotoxicity (Study II)
5.3.1 Weight and body composition
The absolute body weight of the OE-NPYDβH mice had declined at weeks 5 and 6 
after DOX treatment, an effect that was not evident in WT mice (Fig. 6C). In
OE-NPYDβH mice, DOX significantly decreased lean mass gain whereas in WT mice
there was no statistically significant difference in lean mass gain between saline and 
DOX treatment (Fig. 6F). Taken together, the body weight and gain in fat mass were 
decreased in DOX-treated mice regardless of the genotype while the lean mass gain
was reduced significantly only in the OE-NPYDβH mice, suggesting that the
OE-NPYDβH mice were more severely affected by DOX.
5.3.2 Gene expression analysis
5.3.2.1 NPY-related genes
Npy expression in the heart was overall low, as evidenced by the low Ct values in 
qPCR, but the expression level was found to be over ten times higher in OE-NPYDβH 
mice than in WT mice (Fig. 20A). DOX treatment did not alter Npy expression. 
There were no differences in neuropeptide Y 1 receptor expression levels (Fig. 20B)
and the expression level of neuropeptide Y 5 receptor was below the reliable qPCR
detection level. In the transgenic OE-NPYDβH model, in addition to neuronal tissue, 
heart is the only tissue where Npy gene expression has been quantified and found to 
be upregulated. Nonetheless, the higher expression observed in this study more likely
represents the expression in the intracardiac noradrenergic neurons rather than
cardiac myocytes (McDermott & Bell 2007). In the OE-NPYDβH mice, Npy
expression is driven under the dopamine-β-hydroxylase promoter (DβH) targeting
the transgene expression to noradrenergic neurons and showing very little ectopic
expression (Ruohonen, et al. 2008). As the gene expression in heart was assumed to
be low on an absolute scale, the direct effects on cardiac tissue are likely to have
originated from the SNS-derived NPY. The increase of Npy gene expression in the
heart tissue might represent the increase during mild chronic stress, but most likely,
it is not equivalent to elevated NPY levels measured from plasma of human patients
that have been associated with poor survival in HF (Hulting, et al. 1990).
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Figure 20. Relative expression levels of NPY-related genes in the heart of saline and doxorubicin 
(DOX) -treated wild-type (WT) and OE-NPYDβH (OE-NPY) mice (n=7–8/group).
A) Neuropeptide Y (Npy) and B) neuropeptide Y 1 receptor (Npy1R) level. Values are 
presented as means ± SEM, ### P<0.001 two-way ANOVA genotype effect. Reprinted
with permission from Mattila et al. Cardiovascular Toxicology, 2020; 20: 328–33.
5.3.2.2 Genes involved in calcium cycling and contractility
Concerning calcium cycling, there were no differences between the OE-NPYDβH and 
WT genotypes in Serca2a and RyR2 expression (Fig. 11A, B). Interestingly, in the
OE-NPYDβH mice, Pln expression tended to be decreased (Fig. 21A) and 
β-myosin heavy chain (Mhc-β) expression was significantly decreased when the
treatment groups were analyzed together (Fig. 21B). There were no differences in
the expression level of the α-myosin heavy chain (Mhc-α) (Fig. 21C). In previous
studies, DOX has been reported to increase the Mhc-β expression (Boucek, et al.
1999, Umlauf & Horký 2002, Kucerova, et al. 2015, Doka, et al. 2017) but here, no 
response to DOX was seen. The reductions in Mhc-β and Pln have been associated
with improved contractility (Abraham, et al. 2002, Iwanaga, et al. 2004, Tsuji, et al.
2009, Kucerova, et al. 2015, Doka, et al. 2017), which could fit with the known
effects of NPY on cardiac contractility (McDermott & Bell 2007). However, this is
not supported by the echocardiography results, as DOX-induced reductions in both
EF and FS tended to be larger in OE-NPYDβH mice (Fig. 9A, B). Thus, these
alterations in Mhc-β and Pln expression may rather point to a compensation caused
by NPY overexpression that render the mice more susceptible to the DOX-induced
cardiotoxicity. There were no significant changes in myofibroblast marker α-Sma, 
though the expression level seemed to be higher in the OE-NPYDβH mice (Fig. 12I).
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Figure 21. Relative expression levels of genes involved in calcium cycling and contractility in the
heart of saline and doxorubicin (DOX) -treated wild-type (WT) and OE-NPYDβH 
(OE-NPY) mice (n=5–8/group). A) Phospholamban (Pln), B) β-myosin heavy chain 
(Mhc-β), C) α-myosin heavy chain (Mhc-α) level. Values are presented as means ±
SEM. # P<0.05, P=0.088 two-way ANOVA genotype effect. Modified from publication II.
5.3.3 Overview of the effects of NPY on the DOX-induced
cardiotoxicity
Previous studies have shown a diverse role of NPY in different types of pathological
processes in the heart, involving also DOX-induced cardiotoxicity (Ananda, et al.
2012, Matyal, et al. 2013, Shanks & Herring 2013, Herring 2015, Özkaramanli Gür, 
et al. 2017, Tan, et al. 2018). However, in the current study, transgenic NPY
overexpression had very little effect on the heart on its own, even when the
expression level of Npy, measured on a relative scale, was notably higher in the
OE-NPYDβH mice. As the effects of NPY overexpression were evaluated with respect
to DOX-induced cardiotoxicity, the significantly reduced lean mass gain and the
likelihood to larger declines in EF and FS, as evidenced by a tendency, suggested
that DOX had affected the OE-NPYDβH mice more severely. 
5.4 The effects of NPY overexpression on diet-
induced obesity and type 2 diabetes models
(Study III)
5.4.1 Metabolic phenotype
Both WD-fed genotypes demonstrated DIO compared to chow-fed lean mice, 
evidenced by increased body weight, white adipose tissue mass and fasting blood
glucose levels (P < 0.001, diet effect, two-way ANOVA). Body weight did not differ
between OE-NPYDBH and WT mice, however, the blood glucose levels were higher
in the OE-NPYDBH genotype in lean and DIO mice when the treatment groups were
analyzed together (P < 0.05, genotype effect, two-way ANOVA. The metabolic
phenotype of T2D mice in the current study has been published previously (Ailanen,
et al. 2017). WD combined with low-dose STZ resulted in fasting hyperglycemia
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Results and discussion
(blood glucose > 13 mmol/L) in OE-NPYDBH but not in WT mice, thus suggesting
that the overexpression of NPY had increased the susceptibility of the OE-NPYDBH 
mice to develop a T2D-like state.
5.4.2 Echocardiography analysis
The echocardiography assessment was conducted 13 weeks after the onset of WD.
In DIO WT mice, the internal diameter of the left ventricle in diastole was decreased
in comparison to lean mice of the same genotype, a difference that was not present
in OE-NPYDBH mice (Fig. 22A). Moreover, DIO mice displayed a decreased left
ventricle internal diameter in systole when the genotypes were analyzed together
(Fig. 22B). The echocardiography-based measurement revealed a reduced left
ventricular mass (Fig. 22C), and the weight of heart was also decreased in DIO mice 
(Fig. 22D) when the genotypes were analyzed together. No genotype differences
were witnessed in left ventricular mass or heart weight, nor were there any
differences in the EF between the diets or genotypes.
Despite the demonstrated DIO state, in the current study, WD of 13 weeks may
not have been sufficiently severe to provoke functional changes in the heart, although
some studies reported a decline of functional parameters within a comparable HFD
period (Zhang, Y., et al. 2015, Wang, et al. 2017, Li, et al. 2018). Furthermore, 
studies utilizing a comparable diet setting (Zhang, Y., et al. 2015), or longer diets
(Calligaris, et al. 2013, Liang, et al. 2015) have reported hypertrophy and increased
heart weight in HFD, while no prior study could be located where a decreased heart
weight had been reported.
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Figure 22. Echocardiography data and heart weight of lean and diet-induced obese (DIO) wild-type 
(WT) and OE-NPYDBH (OE-NPY) mice (n=7–10/group). A) Left ventricle internal
diameter; diastole (LVID; diastole), B) left ventricle internal diameter; systole (LVID;
systole), C) left ventricle mass corrected (LV mass corrected), D) heart weight. Data is 
presented as mean ± SEM. A) *** P<0.001 Sidak post-hoc test following two-way 
ANOVA, diet effect within genotype, B)–D) * P<0.05 and *** P<0.001 two-way ANOVA
diet effect. Modified from publication III.
5.4.3 Hemodynamic properties
Hemodynamics were studied in vivo by telemetry from carotid artery in lean state
and DIO mice. The average of 48 hours recording revealed elevated MAP during 
both light and dark period in OE-NPYDBH mice compared to WT mice, without any
difference between the diets (Fig. 23A, B). Lean mice displayed no difference
between the genotypes in MAP in their response to the alpha1-receptor agonist PE. 
In both genotypes, in the DIO state, the response to PE was augmented, with the 
MAP being higher in WT than in OE-NPYDBH mice (Fig. 23C). In lean state, atropine
increased HR less in OE-NPYDBH mice compared to WT mice, while in the DIO state,
the atropine-induced increase in HR was abolished in WT mice (Fig. 23D). To
further evaluate whether the changes in MAP and HR resulted from increase in
sympathetic activity, the noradrenaline levels were analyzed. DIO increased
noradrenaline levels as compared to lean state, with OE-NPYDBH mice having lower
levels compared to WT mice in DIO state (III: Fig. 7A).  
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Results and discussion
Vascular reactivity was studied ex vivo by wire myography from lean, DIO and 
T2D state mice. The maximal vasoconstrictive response of the mesenteric artery to
PE was augmented in DIO and T2D as compared to lean state, especially in WT mice
(Fig. 23E). In the PE-response curve, the contraction response in the mesenteric 
artery was reduced in OE-NPYDBH genotype compared to WT mice in both DIO and 
T2D (III: Fig. 4C, E). With respect to vasorelaxation, the maximal response of the
aorta to ACh was decreased in DIO and T2D compared to the lean state (P < 0.01, 
diet effect, two-way ANOVA). When inhibiting the NO production with L-NNA 
prior to the ACh treatment, the ACh response was less effectively blunted in the
OE-NPYDBH DIO state mice (III: Fig. 6E) showing that the contribution of NO to
vasorelaxation was reduced in OE-NPYDBH mice. The relaxation response to the NO-
donor SNP was attenuated in OE-NPYDBH mice in lean state as compared to WT 
mice (III: Fig. 6G) suggesting that endothelium-independent vasodilatation was
impaired in OE-NPYDBH mice aorta.
Taken together, the results of the hemodynamic studies showed that the 
overexpression of Npy led to a cardiovascular phenotype to some extent resembling 
DIO. Nonetheless, the mechanisms behind the changes are somewhat different.
Npy overexpression and DIO both suppressed parasympathetic control of the heart, 
as evidenced by the suppressed response to atropine. Thus, the life-long transgenic
NPY excess may provide a mechanism for elevated risk of cardiovascular disease
linked with NPY. Only DIO (and not excess of Npy) increased sympathetic 
activity, as reflected in the higher in vivo MAP increase and ex vivo arterial
vasoconstriction in response to PE, and the elevated urine noradrenaline level. 
Against our hypothesis, the overexpression of Npy had no synergistic effect with
DIO. This could be explained by the attenuated increase in sympathetic activity
and the vascular responses by NPY. The arterial vasoconstriction was similarly
attenuated in response to PE in DIO and T2D state OE-NPYDBH mice. However, in 
the ACh-induced vasodilation, the genotype difference in the NO-component
evident in DIO was abolished by T2D. NPY excess did not aggravate the vascular
function in T2D state.
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Figure 23. Hemodynamic properties of wild-type (WT) and OE-NPYDβH (OE-NPY) mice. Properties
in lean state, in diet-induced obesity (DIO) (A-D) and in type 2 diabetic (T2D) state (E), 
studied by telemetry (A-D) or by myography (E). A-B) Average mean arterial pressure
(MAP) on A) light and B) dark period, n=7–8/group, # P<0.05; P=0.05 comparing different
genotypes with two-way ANOVA. C) MAP response to phenylephrine (PE, 2-32 µg/kg,
doses in randomized order, i.v.), n=3-4/group, ## P<0.01 comparing different genotypes 
in DIO and * P<0.05 and *** P<0.001 comparing different diets with two-way ANOVA
within a genotype. D) Heart rate (HR) response to atropine (2 mg/kg, i.p.), n=7/group, 
# P<0.05 comparing different genotypes on lean state and * P< 0.05 comparing different
diets within WT mice with Bonferroni post-hoc test following two-way ANOVA. 
E) Maximal response to PE in mesenteric arteries, n=5-7/group, # P<0.05 comparing
different genotypes and P<0.01 comparing different diets with two-way ANOVA. Data is
presented as mean ± SEM. Modified from publication III.
5.4.4 Histological analysis
When the hearts were assessed histologically, lean mice displayed normal hearts
with no nuclear atypia or changes in nuclear size (Fig. 24A, B). In DIO mice,
hypertrophy of the myocardial cell nuclei (Fig. 24C, arrow) and some perivascular
oedema (Fig. 24D, arrows) were evident. In T2D cohort, OE-NPYDBH mice showed
signs of cytoplasmic degeneration (Fig. 24E, arrows). In the T2D cohort, 71% of
both genotypes displayed myocardial degeneration of tissue (scale 1/3) whereas 22%
of lean and 33% of DIO OE-NPYDBH mice, but none of the lean and DIO WT mice 
exhibited signs of degeneration (n=7–10/group). 
Several studies have reported disorganization of myofibers in HFD, but in most
cases, the length of the diet has been at least double compared to our study (Cao, 
et al. 2016, Lucas, et al. 2016, Daltro, et al. 2017) or the mice were notably older
(Lucas, et al. 2016, Hung, et al. 2017). However, with a comparable diet duration to 
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ours, histological damage has been reported in some studies (Wang, et al. 2017, 
Kondo, et al. 2018). On the other hand, regarding STZ-induced T2D model, less than
half of our diet period has been reported to lead to detrimental findings (Huang, 
et al. 2017). 
Figure 24. Histological findings in the paraffin sections of the heart stained with hematoxylin/eosin.
A–B) Wild-type mouse in lean state and C) in diet-induced obesity (DIO), D) OE-NPYDBH 
mouse in DIO, E) OE-NPYDBH mouse in type 2 diabetic state. Arrows indicate C)
hypertrophy of the myocardial cell nuclei, D) perivascular oedema, and E) cytoplasmic
degeneration. Scale bar indicates 100 µm length. From publication III.
5.4.5 Gene expression analysis
Interestingly, the expression of collagen I alpha 2 (Col1a2), a fibrosis marker, was
lower in the hearts of DIO mice as compared to lean mice when the genotypes were
analyzed together (Fig. 25A). There were no differences in the expression levels of 
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the cytokine marker, transforming growth factor beta 1 (Tgf-β1) or mitochondrial 
marker, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (Pgc-
1α) (Fig. 25B, C).
A study utilizing a comparable research set-up (Li, et al. 2018), as well as studies
where the mice have consumed longer HFD (Calligaris, et al. 2013, Daltro, et al.
2017) have reported increased Tgf-β1 and Col1 expression in HFD. In the current
study, no explanation was found for the lower Col1a2 fibrosis marker expression in 
the hearts of DIO mice.
Figure 25. Relative gene expression level in the heart of lean and diet-induced obese (DIO) wild-
type (WT) and OE-NPYDBH (OE-NPY) mice (n=9–10/group). A) Collagen 1 a 2 (Col1a2), 
B) Transforming growth factor beta 1 (Tgf-β1) C) Peroxisome proliferator-activated
receptor gamma coactivator 1 alpha (Pgc-1α) level. Data is presented as mean ± SEM.
* P<0.05 two-way ANOVA diet effect. Modified from publication III.
5.5 Methodological considerations
5.5.1 Animals
The C57BL/6 mouse strain is the most well-known inbred mouse strain utilized in 
animal studies (Mekada, et al. 2009). The two main substrains of C57BL/6 are
C57BL/6J and C57BL/6N, and the latter is used in all of the Studies I-III. In Studies 
II and III, an additional cohort of OE-NPYDβH mice, originating from the same 
C57BL/6N background was used. Male mice were used in order to eliminate the
effects of the oestrus cycle.
The C57BL/6 strain has been reported to be prone to develop atherosclerosis 
when fed with a high fat diet (Schreyer, et al. 1998). Furthermore, there are various
noteworthy genotypic and phenotypic differences between the C57BL/6 substrains,
but not all the studies have reported which of the substrains was used (Fontaine &
Davis 2016). The substrain C57BL/6N has maintained its stability well as no genetic
variation was found in genotyping panels after 30 years of extensive breeding
(Mekada, et al. 2009). C57BL/6N mice have been found to develop hyperglycaemia 
and hyperinsulinaemia after three 3 weeks of HFD (Kleinert, et al. 2018), however,
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Results and discussion
the substrain C57BL/6J is more commonly used in metabolic research as it is more 
susceptible to diabetes and DIO (Fontaine & Davis 2016). In the DOX-induced
cardiotoxicity studies that have been reviewed in this thesis (see Table 2), only one 
had utilized C57BL/6N mice with certainty (many of the reviewed studies did not
specify the substrain of the mice), and the results of that study were in line with ours,
with only minor functional changes (Matsumura et al. 2018). 
Single housing versus group housing of mice is a much debated issue. While
single housing may predispose mice to stress due to the lack of social contacts, group
housed mice may be predisposed to aggressive behavior between the males (Gonder
& Laber 2007). In a previously published study, it was concluded that no general
recommendations could be made, as mice seem to respond in a context-dependent
manner, and thus the housing protocol needs to be considered individually in each 
case (Kappel, et al. 2017). In studies I and II, the mice were single-housed to ensure
the proper recovery from the DOX administration. In study III, the mice were housed 
in groups.
5.5.2 Heart failure models
In Studies I and II, the dose of DOX was carefully considered on the basis of previous
studies (Li, et al. 2006, Neilan, et al. 2006). The intraperitoneal dosing was
performed under anaesthesia, thus the injection site could be determined in a very 
fine-tuned manner as the mice were unconscious and not moving. The response to 
DOX was slightly milder than would have been expected based on the literature, yet
signs of cardiotoxicity were evident and marked differences were found in DOX-
treated mice in comparison to the control animals.
In Study II, the hypothesis was that OE-NPYDβH genotype would be expected to
exacerbate the DOX-induced cardiotoxicity. The OE-NPYDβH mouse model displays
a metabolic syndrome-like phenotype rather similar to the human NPY L7P 
polymorphism, which has been found to be a risk factor for type 2 diabetes and
cardiovascular diseases (Pesonen 2008). In addition, the OE-NPYDβH mice have been
reported to be more susceptible to vascular damage-induced endothelial hypertrophy
(Ruohonen, et al. 2009). Instead, here, the effects seemed to be rather minor. This
might be because of moderate DOX-response or the limited Npy overexpression in 
the heart, i.e. the actual absolute level was low even although the expression was
many times higher than in WT mice.
In study III, in order to obtain DIO, a high caloric rodent diet was used to mimic
the highly processed Western type foods that many humans are consuming. The DIO
state was reached independently of the genotype, which is in line with previous
results (Vähätalo, et al. 2015, Ailanen, et al. 2018). To induce T2D, the DIO state 
mice were administered a low dose of streptozotocin. Previously published results
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have verified this model in terms of the metabolic phenotype (Ailanen, et al. 2017).
Based on our findings in Study III, parasympathetic control of the heart was
suppressed by both DIO and NPY, but only DIO increased sympathetic activity.
Contrary to the original hypothesis, overexpression of NPY did not augment the
effects of DIO, and this may be mediated to some extent by the attenuated increase
in sympathetic activity and vascular responses by NPY. The findings concerning
decreased Col1a2 expression and lower weight of heart in DIO mice, and decreased
left ventricular end-diastolic diameter in DIO WT mice were contradictory to 
previous research, and no explanation was found with respect to technical research
settings. However, the comparison between these results and the other studies should 
be conducted with caution since a strong genetic component has been shown to exist
in the cardiac structure and function (Wang, et al. 2016).
5.5.3 Gene therapy
Lentiviral-mediated gene transfer is a well-established method (Selkirk 2004, Ly 
2007, Niwano, et al. 2008). The lentiviral vector is a very suitable choice for HF
gene therapy as it is capable of infecting non-dividing cardiomyocyte cells and it
offers long-term overexpression by integrating into the host genome. The lentiviral
vector used in this study represents a second-generation viral construct in which the 
possibility of a multi-recombination event has been eliminated, preventing the
generation of a self-replicative vector. The lentiviral dose was determined by
quantifying the GFP protein expression produced by the viral vector in the in vitro
infected cells. In the bicistronic vector backbone, the GFP gene is located
downstream from the Serca2a gene, the IRES (internal ribosome entry site)
separating these two genes. IRES is known to affect the expression of the
downstream gene, the expression range being 6-100% and the typical expression
20-50% compared to the upstream gene which is located next to the promoter
(Mizuguchi, et al. 2000, Chinnasamy, et al. 2006). Thus, the in vivo expression of
SERCA2a is comparable to GFP expression or probably somewhat higher. In study
I, the expression of the Serca2a gene was not quantified using qPCR. There were no 
antibodies suitable at the time for the quantification of SERCA2a protein in the tissue 
samples as every antibody available was produced in mice, and thus inapplicable for
histological samples derived from mice. As the viral injection area in the heart was
narrow, the local protein isolation, limited to the exact injection site, was not an 
option and the Western blot analysis was not sensitive enough to detect transgenic
SERCA2a overexpression. In addition, although the valid SERCA2a protein product
was confirmed in vitro, however, the biological activity of the protein product was
not evaluated. 
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Results and discussion
By performing ultrasound-guided intramyocardial injection, the viral vectors can
be delivered directly into the wall of the left ventricle, without the need for invasive 
open chest surgery. Direct injection caused only a minor needle track without any 
observed deleterious effects on cardiac function. The area covered by gene transfer
in the anterior wall of the left ventricle was not extensive (comprising a few hundred
micrometers along the needle track). It is unclear whether strong transgene 
expression in a smaller number of cells produces a similar therapeutic effect as lower
expression in a greater number of cells (Yla-Herttuala 2017b). In addition, as
SERCA2a is a membrane protein of the sarcoplasmic reticulum, each cardiomyocyte
is required to be transduced by the viral vector in order to achieve a therapeutic 
response in the cardiomyocyte, and in this respect it differs from a paracrine gene 
therapy product (such as VEGF) which is able to affect also the nearby cells. 
However, in this model, the relatively limited number of SERCA2a overexpressing 
cells did occasion a clinically meaningful result as a marked improvement of cardiac 
function was observed. The delivery method chosen in this thesis, intramyocardial
injection, is viewed as being much more efficient in animal models than intra-arterial 
delivery, and it has also been utilized in many recent clinical trials, especially with
the help of the injection targeting method NOGA mapping (Hassinen, et al. 2016, 
Hartikainen, et al. 2017, Yla-Herttuala & Baker 2017).
5.5.4 Physiological aspects of study methods
The in vivo and ex vivo study methods and the biochemical analyses conducted in
this thesis have been previously published and the results can be considered as 
reliable. In preclinical research set-up, the equipment, the protocols and the study 
conditions are not completely standardized and the sample size is relatively small,
and these factors may introduce some variation. Thus, comparing the results between
different independent studies must be performed with caution.
There are some aspects of study methods to be considered. Recording the body
composition by qNMR required immobilization of the conscious mice during the
measurement protocol. Each mouse was measured twice and the mean values were
used as a way of enhancing the accuracy. In echocardiography, the level of
anaesthesia was monitored by the HR and was set at a level not to dampen the
function of the heart. The handling of mice and dosing of substances may have
induced some stress, but there was a habituation period before the actual studies
aimed at minimizing the stress-induced effects that may have occurred. Furthermore, 
to avoid stress, intraperitoneal administration of substances was performed under
anaesthesia when possible (in Studies I and II).
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6 Summary and conclusions
Studies I and II demonstrated that DOX generated cardiotoxicity, which
subsequently could be ameliorated with lentiviral-mediated SERCA2a gene therapy. 
Studies II and III showed that life-long overexpression of NPY may worsen the
DOX-induced cardiotoxicity and lead to cardiovascular alterations resembling DIO.
The main findings and conclusions from the studies conducted in this thesis, as 
reflected in the original aims were:
1. DOX induced cardiotoxicity as demonstrated by a decline in myocardial
function and mass, and a decline in the general condition of the mice. In
addition, harmful alterations of expression levels in the genes modifying
calcium cycling as well as in the marker genes of cardiomyopathy were 
observed, indicating that cellular mechanisms driving detrimental changes 
in the heart had been recruited.
2. The lentiviral vector expressing SERCA2a gene was shown to produce the 
correct SERCA2a protein, and the integration of SERCA2a into the host
genome after intramyocardial injection was confirmed. 
3. The therapeutic effect of the SERCA2a-expressing lentiviral vector was
proven in the DOX-induced HF model, as evidenced by the improvements
in cardiac function.
4. Npy expression was shown to be upregulated in the heart of transgenic
OE-NPYDβH mouse model. The impaired lean mass accumulation and the
tendency towards a larger decrease in the heart function may imply that
neuropeptide Y overexpression increased the susceptibility to
cardiotoxicity in DOX-induced HF model.
5. Npy overexpression suppressed parasympathetic activity while increasing
sympathetic activity. DIO elevated sympathetic activity, but the effect was
attenuated by overexpression of Npy. The vascular disturbances caused by 
Npy and DIO appeared, but were not further aggravated by T2D. The
current model of DIO did not lead to any harmful effects on the heart, but
signs of tissue degradation were seen, especially in T2D heart.
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